Six-membered aromatic ring pyrrolone derivative as well as pharmaceutical composition and application thereof
Patent Information
- Application Number
- CN202380035439.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-09-20
- Filing Date
- 2023-03-02
- Publication Date
- 2024-12-03
AI Technical Summary
Existing PI3Kγ inhibitors are inadequate in terms of selectivity and pharmacokinetic properties, and have poor solubility, failing to meet clinical needs.
A series of six-membered aromatic ring pyrrolidone derivatives were developed, exhibiting excellent selective inhibitory activity against PI3Kγ kinase and improved in vivo pharmacokinetic activity, as well as improved solubility under acidic conditions.
It achieves highly selective inhibition of PI3Kγ with an IC50 value of less than 100 nM, making it suitable for the treatment of diseases related to PI3Kγ activity.
Smart Images

Figure CN119072476A_ABST
Abstract
Description
Six-membered aromatic ring pyrrolidine derivative, its pharmaceutical composition and application
[0001] Related applications
[0002] This application claims priority to the Chinese patent application with application number 202211144337.0, filed on September 20, 2022, entitled “Six-membered aromatic ring pyrrolidine derivatives, their pharmaceutical compositions and applications”, and the Chinese patent application with application number 202210202749.9, filed on March 2, 2022, entitled “Pyridopyrrolidine derivatives, their pharmaceutical compositions and applications”, the entire text of which is hereby incorporated by reference. Technical Field
[0003] The present application relates to the field of medical technology, and in particular to a six-membered aromatic ring pyrrolidone derivative, a pharmaceutical composition thereof, and applications thereof. Background Art
[0004] Phosphoinositide 3-kinases (PI3Ks) are phosphatidyl kinases that phosphorylate the phosphoinositide ring and are classified into three types: type I, type II, and type III. Type I PI3Ks are the most extensively studied. This type is further divided into two subgroups (IA and IB). Class IA PI3Ks include three closely related kinases: PI3Kα, PI3Kβ, and PI3Kδ, which are heterodimers composed of the corresponding catalytic subunit (p110α, p110β, or p110δ) and one of several regulatory subunits. PI3Kα and PI3Kβ are widely expressed and play a role in cell growth, division, and survival (Thomas M, et al., Curr. Opin. Pharmacol., 2008;8:267-274). These two kinases play a role in numerous biological functions, as exemplified by the high embryonic lethality observed in mice lacking either PI3Kα or PI3Kβ. Due to their roles in homeostasis, PI3Kα and PI3Kβ are under clinical evaluation in oncology, and several related compounds are in various stages of clinical development. PI3Kγ, a single class IB isoform, primarily responds to G-protein coupled receptors (GPCRs) and consists of a p110γ catalytic subunit and one of two distinct regulatory subunits. PI3Kγ isoforms are expressed in immune cells and have limited expression in normal and malignant epithelial and connective tissue cells. Studies in PI3Kγ knockout mice have demonstrated that PI3Kγ is important for cell activation and migration in response to certain chemokines (Sasaki T., et al., Science, 2000;287:1040-1046; Hirsch E., et al., Science, 2000;287:1049-1053). PI3Kγ signaling is particularly important for myeloid cell function. Camps et al. described that treatment with the selective PI3Kγ inhibitor AS-60485023 inhibited the progression of joint inflammation and damage in two different mouse models of rheumatoid arthritis (Camps M et al., Nat. Med. 2005, 11, 936-943). Based on the cellular level and efficacy studies observed in various disease models, PI3Kγ inhibitors can potentially be used to treat various diseases, such as inflammation, metabolism, and cancer (Cushing, TD et al., J. Med. Chem. 2012, 55, 8559-8581; Ruckle, T. et al., Nat. Rev. Drug Discovery 2006, 5, 903-918; Stark, AK et al., Curr. Opin. Pharmacol. 2015, 23, 82-91).
[0005] Although selective PI3Kγ inhibitors have been reported in many papers, such as WO2017153527 and WO2020210379, the selectivity and pharmacokinetic parameters of these PI3Kγ inhibitors need to be further improved. In addition, the currently developed compounds have problems such as poor solubility and inability to form salts. Therefore, this technical field also needs to develop PI3Kγ inhibitors with better selectivity and pharmacokinetic properties suitable for later development to better meet clinical needs.
[0006] Summary of the Invention
[0007] In a first aspect, the present application provides a compound represented by formula (I), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof:
[0008] in,
[0009] Ring A is a 5- or 6-membered heteroaryl ring;
[0010] (R0) n Indicates that the hydrogen on ring A is replaced by n R0, n is 0, 1, 2, 3 or 4; each R0 is the same or different and independently represents deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, NR a1 R b1 、-N(R a3 )-C(O)C 1-3 Alkyl, -N(R a3 )-C(O)-deuterated C 1-3 Alkyl, -N(R a3 )-C(O)OC 1-3 Alkyl, -SO2C 1-3 Alkyl, -SO2C 3-6 Cycloalkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl; wherein the 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl are each independently unsubstituted or substituted by 1, 2, or 3 substituents each independently selected from Substituent Group Q;
[0011] Z is N or CR z; R z is hydrogen, halogen or C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3 alkyl);
[0012] U is N or CH;
[0013] W is cyano, ethynyl, -NHSO2N(CH3)2, 5- or 6-membered heteroaryl, or a structure represented by formula (Ia), (Ib), (Ic) or (Id):
[0014] R a 、R b are each independently halogen, C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3 Alkyl), hydroxy substituted C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3 Alkyl) or C 3-6 Cycloalkyl;
[0015] R c For hydroxyl, halogen, C 1-3 Alkyl, deuterated C 1-3 Alkyl, C 3-6 Cycloalkyl, halogenated C 1-3 Alkyl or NR a1 R b1 ;
[0016] Y is C or N;
[0017] is a 5- or 6-membered heteroaryl ring, or a benzene ring;
[0018] p and q are each independently 0, 1, 2 or 3;
[0019] R w1 、R w2 、R w3 、R w4 are independently hydrogen, cyano, halogen, C 1-3 Alkyl, halogenated C 1-3 Alkyl, -N(R a3 )-C(O)C 1-3 Alkyl, -SO2C 1-3 Alkyl, -C(O)NR a1 R b1 or NR a1 R b1 ;
[0020] p1, p2, q1, q2 are each independently 1, 2 or 3;
[0021] R d is halogen (in some embodiments, fluorine);
[0022] L 21 , L 22 Each independently is -(CR e2 R f2 ) m2 -; m2 is 1, 2 or 3;
[0023] Y2 is NR g2 or O;
[0024] R e2 、R f2 are independently hydrogen, hydroxy, oxo, C 1-3 Alkyl or -C(O)C 1-3 alkyl;
[0025] R g2 For hydrogen, C 1-3 Alkyl or -C(O)C 1-3 alkyl;
[0026] R1 and R2 are each independently C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3 Alkyl), halogenated C 1-8 Alkyl (in some embodiments, halogenated C 1-6 Alkyl, in other embodiments, is halogenated C 1-3 Alkyl) or C 3-6 Cycloalkyl; the C 3-6 Cycloalkyl is unsubstituted or substituted by 1 or 2 groups independently selected from halogen and C 1-3 Substitution of alkyl groups;
[0027] The substituent group Q is halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl;
[0028] R a1 、R b1 are independently hydrogen, C 1-3 Alkyl or acetyl, or R a1 、R b1 Together with the nitrogen atom to which it is connected, it forms a 4- to 6-membered saturated monocyclic heterocycle; the 4- to 6-membered saturated monocyclic heterocycle is unsubstituted or substituted by 1, 2 or 3 substituents independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NH2, -C(O)NH(C 1-3 alkyl), -C(O)N(C 1-3 Alkyl)2, -C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 cycloalkyloxy and 3- to 6-membered heterocycloalkyl;
[0029] R a3 is hydrogen or C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3 alkyl).
[0030] In some embodiments, W is cyano, ethynyl, or -NHSO2N(CH3)2.
[0031] In some embodiments, W is a 5- or 6-membered heteroaryl group selected from the group consisting of thienyl, furanyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, pyrrolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, tetrazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and tetrazinyl.
[0032] In some embodiments, the 5- or 6-membered heteroaryl group in W is selected from one of the following structures:
[0033] In some embodiments, the 5- or 6-membered heteroaryl group in W is selected from one of the following structures:
[0034] In some embodiments, W is a structure represented by formula (Ia).
[0035] In some embodiments, Formula (Ia) is selected from one of the following structures:
[0036] In some embodiments, Formula (Ia) is selected from one of the following structures:
[0037] In some embodiments, W is a structure represented by formula (Ib) or (Ic).
[0038] Optionally, is a benzene ring or a 5- or 6-membered heteroaryl ring selected from the group consisting of a thiophene ring, a furan ring, a thiazole ring, an isothiazole ring, an imidazole ring, an oxazole ring, a pyrrole ring, a pyrazole ring, a 1,2,3-triazole ring, a 1,2,4-triazole ring, a 1,2,5-triazole ring, a 1,3,4-triazole ring, a tetrazole ring, an isoxazole ring, a 1,2,3-oxadiazole ring, a 1,2,4-oxadiazole ring, a 1,2,5-oxadiazole ring, a 1,3,4-oxadiazole ring, a thiadiazole ring, a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a triazine ring and a tetrazine ring.
[0039] In some embodiments, Formula (Ib) is selected from one of the following structures:
[0040] In some embodiments, the structure represented by formula (Ic) is selected from the following structures:
[0041] In some embodiments, W is a structure represented by formula (Id).
[0042] In some embodiments, the structure represented by (Id) is selected from the following structures:
[0043] In some embodiments, Ring A is a 5- or 6-membered heteroaryl ring selected from the group consisting of a thiophene ring, a furan ring, a thiazole ring, an isothiazole ring, an imidazole ring, an oxazole ring, a pyrrole ring, a pyrazole ring, a 1,2,3-triazole ring, a 1,2,4-triazole ring, a 1,2,5-triazole ring, a 1,3,4-triazole ring, a tetrazole ring, an isoxazole ring, a 1,2,3-oxadiazole ring, a 1,2,4-oxadiazole ring, a 1,2,5-oxadiazole ring, a 1,3,4-oxadiazole ring, a thiadiazole ring, a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a triazine ring, and a tetrazine ring.
[0044] In some embodiments, Ring A is a thiazole ring.
[0045] In some embodiments, n is 2.
[0046] In some embodiments, each R0 is the same or different and is independently C 1-3 Alkyl, -NH-C(O)C 1-3 Alkyl, -NH-C(O)-deuterated C 1-3 Alkyl or -NH-C(O)OC 1-3 alkyl.
[0047] In some embodiments, in formula (I), It is the structure shown in formula (a):
[0048] R 01 、R 02 As defined in R0, each is independently deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, NR a1 R b1 、-N(R a3 )-C(O)C 1-3 Alkyl, -N(R a3 )-C(O)-deuterated C 1-3 Alkyl, -N(R a3 )-C(O)OC 1-3 Alkyl, -SO2C 1-3 Alkyl, -SO2C 3-6 Cycloalkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl or 5- to 6-membered heteroaryl; wherein the 3- to 6-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaryl are each independently unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from Substituent Group Q.
[0049] In some embodiments, R 01 Halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkyl or halogenated C 1-3 Alkoxy; R 02 -NH-C(O)C 1-3 Alkyl, -NH-C(O)-deuterated C 1-3 Alkyl or -NH-C(O)OC 1-3 alkyl.
[0050] In some embodiments, R 01 is methyl, ethyl, n-propyl or isopropyl. In other embodiments, R 01 It is a methyl group.
[0051] In some embodiments, R 02 -NH-C(O)C 1-3 Alkyl, -NH-C(O)-deuterated C 1-3 Alkyl or -NH-C(O)OC 1-3 In other embodiments, R 02 It is -NH-C(O)CH3, -NH-C(O)-CD3 or -NH-C(O)OCH3.
[0052] In some embodiments, in formula (I), for
[0053] In some embodiments, R1 is monochloromethyl, dichloromethyl, trichloromethyl, monochloroethyl, 1,2-dichloroethyl, trichloroethyl, monobromoethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, monofluoro-substituted cyclopropyl, or monofluoro-substituted cyclobutyl; R2 is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, monofluoro-substituted cyclopropyl, or monofluoro-substituted cyclobutyl.
[0054] In some embodiments, R1 is cyclopropyl, cyclobutyl, or trifluoromethyl.
[0055] In some embodiments, R2 is methyl, ethyl, cyclopropyl, or cyclobutyl.
[0056] In some embodiments, in formula (I), Select one of the following structures:
[0057] In some embodiments, in formula (I), Select one of the following structures:
[0058] In some embodiments, Z is N or CH.
[0059] In some embodiments, the 5- or 6-membered heteroaryl (ring) in the above structural formulas and groups is independently selected from the group consisting of: thienyl, furyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and tetrazinyl.
[0060] In some embodiments, the 5- or 6-membered heteroaryl (ring) is independently selected from the following structures:
[0061] In some embodiments, the 3- to 6-membered heterocycloalkyl groups in the above structural formulas and groups are 4- to 6-membered heterocycloalkyl groups, each independently selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyrrolyl, oxazolidinyl, dioxolane, piperidinyl, piperazinyl, morpholinyl, dioxane, thiomorpholinyl, thiomorpholine-1,1-dioxide, tetrahydropyranyl, pyrrolidin-2-one, dihydrofuran-2(3H)-one, morpholin-3-one, piperazin-2-one, and piperidin-2-one.
[0062] In some embodiments, the compound of formula (I) is selected from any one of the following structures:
[0063] The second aspect of the present application provides a pharmaceutical composition comprising the compound described in the first aspect of the present application, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and a pharmaceutically acceptable carrier.
[0064] The third aspect of the present application provides the use of the compound described in the first aspect of the present application, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and the pharmaceutical composition described in the third aspect of the present application in the preparation of a drug for treating or preventing diseases related to or mediated by PI3Kγ activity.
[0065] In some embodiments, the disease associated with or mediated by PI3Kγ activity is inflammation, metabolic disease, or cancer.
[0066] The fourth aspect of the present application provides the compound described in the first aspect of the present application, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or the pharmaceutical composition described in the second aspect of the present application for treating or preventing diseases associated with or mediated by PI3Kγ activity.
[0067] The fifth aspect of the present application provides a method for treating or preventing a disease associated with or mediated by PI3Kγ activity, comprising administering to a subject a therapeutically effective amount of the compound described in the first aspect of the present application, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a therapeutically effective amount of the pharmaceutical composition described in the second aspect of the present application.
[0068] It should be understood that within the scope of this application, the above-mentioned technical features of this application and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or optional technical solutions. Due to space limitations, they will not be listed here one by one. DETAILED DESCRIPTION
[0069] After extensive and in-depth research, the applicant unexpectedly discovered a class of six-membered aromatic ring pyrrolidine derivatives that exhibit excellent selective PI3Kγ kinase inhibitory activity, enhanced in vivo pharmacokinetic activity, and solubility in acidic conditions. Therefore, this series of compounds is expected to be developed as selective PI3Kγ inhibitors for the treatment and / or prevention of diseases associated with PI3Kγ activity. Based on this, the applicant completed the present application.
[0070] Definition of terms
[0071] In order to more clearly understand the technical content of this application, the terms of this application are further explained below.
[0072] "Alkyl" refers to straight-chain and branched saturated aliphatic hydrocarbon groups. 1-8 "Alkyl" refers to an alkyl group having 1 to 8 carbon atoms, for example, C 1-6 Alkyl, in some embodiments C 1-3Alkyl; Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl pentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched-chain isomers thereof.
[0073] "Alkenyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group having one or more carbon-carbon double bonds (C=C). 2-8 "Alkenyl" refers to an alkenyl group having 2 to 8 carbon atoms, for example, C 2-6 Alkenyl, in some embodiments, is C 2-4 Alkenyl is similarly defined; non-limiting examples of alkenyl include ethenyl, propenyl, isopropenyl, n-butenyl, isobutenyl, pentenyl, hexenyl, and the like.
[0074] "Alkynyl" refers to a straight-chain or branched unsaturated aliphatic hydrocarbon group having one or more carbon-carbon triple bonds. 2-8 "Alkynyl" refers to an alkynyl group having 2 to 8 carbon atoms, for example, C 2-6 Alkynyl, in some embodiments, is C 2-4 Alkynyl is similarly defined; non-limiting examples of alkynyl include ethynyl, propynyl, n-butynyl, isobutynyl, pentynyl, hexynyl, and the like.
[0075] The terms "cycloalkyl" and "cycloalkyl ring" are used interchangeably and refer to a saturated monocyclic, bicyclic or polycyclic hydrocarbon group, which may be fused to an aryl or heteroaryl group. The cycloalkyl ring may be optionally substituted. In certain embodiments, the cycloalkyl ring contains one or more carbonyl groups, such as an oxo group. "C 3-8"Cycloalkyl" refers to a monocyclic cycloalkyl group having 3 to 8 carbon atoms. Non-limiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclobutanone, cyclopentanone, cyclopentane-1,3-dione, etc. For example, C 3-6 Cycloalkyl, including cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. 8-10 "Cycloalkyl" refers to a fused bicyclic hydrocarbon radical having 8 to 10 ring atoms, C 8-10 Non-limiting examples of cycloalkyl groups include
[0076] The terms "spirocyclyl" and "spirocycle" are used interchangeably and refer to polycyclic hydrocarbon groups in which the monocyclic rings share a carbon atom (called a spiro atom). "7- to 11-membered spirocyclyl" refers to a spirocycle having 7 to 11 ring atoms. Spirocycles are classified as bispirocycles or polyspirocycles according to the number of rings, for example, bispirocycles. In some embodiments, the bispirocycle is a 4-membered / 5-membered, 5-membered / 5-membered, or 5-membered / 6-membered bispirocycle. For example:
[0077] The terms "cycloalkenyl" and "cycloalkenyl ring" are used interchangeably and refer to a monocyclic, bicyclic, or polycyclic hydrocarbon group containing one or more carbon-carbon double bonds within the ring, which may be fused to an aryl or heteroaryl group. The cycloalkenyl ring may be optionally substituted. In certain embodiments, the cycloalkenyl ring contains one or more carbonyl groups, such as an oxo group. "C 3-8 "Cycloalkenyl" refers to a monocyclic cycloalkenyl group having 3 to 8 carbon atoms. For example, C 3-6 Cycloalkenyl. Non-limiting examples of cycloalkenyl groups include cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, cyclopentyl-2-en-1-one, cyclohexyl-2,5-dien-1-one, cyclohexyl-2-en-1-one, cyclohex-2-ene-1,4-dione, and the like.
[0078] The terms "heterocycloalkyl" and "heterocycloalkyl ring" are used interchangeably and refer to a cycloalkyl group comprising at least one heteroatom selected from nitrogen, oxygen and sulfur, which group may be fused to an aryl or heteroaryl group. The heterocycloalkyl ring may be optionally substituted. In certain embodiments, the heterocycloalkyl ring contains one or more carbonyl or thiocarbonyl groups, such as groups comprising oxo and thio. "3 to 8 membered heterocycloalkyl" refers to a monocyclic cyclic hydrocarbon group having 3 to 8 ring atoms, wherein 1, 2 or 3 ring atoms are heteroatoms selected from nitrogen, oxygen and sulfur, such as 4 to 8 membered heterocycloalkyls, 3 to 6 membered heterocycloalkyls in certain embodiments, having 3 to 6 ring atoms, wherein 1 or 2 ring atoms are heteroatoms selected from nitrogen, oxygen and sulfur, and 4 to 6 membered heterocycloalkyls in other embodiments, having 4 to 6 ring atoms, wherein 1 or 2 ring atoms are heteroatoms selected from nitrogen, oxygen and sulfur. Non-limiting examples include aziridine, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyrrolyl, oxazolidinyl, dioxolanyl, piperidinyl, piperazinyl, morpholinyl, dioxane, thiomorpholinyl, thiomorpholine-1,1-dioxide, tetrahydropyranyl, azetidin-2-onyl, oxetan-2-onyl, dihydrofuran-2(3H)-onyl, pyrrolidin-2-onyl, pyrrolidin-2,5-dionyl, dihydrofuran-2,5-dionyl, piperidin-2-onyl, tetrahydro-2H-pyran-2-onyl, piperazin-2-onyl, morpholin-3-onyl, and the like. The terms "6- to 12-membered heterocycloalkyl" and "6- to 12-membered fused heterocycloalkyl" are used interchangeably and refer to a fused bicyclic cyclic hydrocarbon group having 6 to 12 ring atoms, of which 1, 2, or 3 ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur. The terms "8- to 10-membered heterocycloalkyl" and "8- to 10-membered fused heterocycloalkyl" are used interchangeably and refer to a fused bicyclic cyclic hydrocarbon group having 8 to 10 ring atoms, of which 1, 2, or 3 ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur. Non-limiting examples include hexahydro-1H-furo[3,4-c]pyrrole, octahydro-1H-cyclopenta[c]pyridine, hexahydro-1H-pyrrolo[2,1-c][1,4]oxazine, octahydropyrrolo[1,2-a]pyrazine, hexahydropyrrolo[1,2-a]pyrazin-4(1H)-one, octahydrocyclopenta[c]pyrrole, and the like. In fused bicyclic heterocycloalkyl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom as valence permits.Bicyclic heterocycloalkyl systems may include one or more heteroatoms in one or both rings.
[0079] The terms "heterospirocyclyl" and "heterospirocycle" are used interchangeably and refer to a monovalent non-aromatic ring system having two monocycles sharing one carbon atom, which is composed of carbon atoms and heteroatoms selected from nitrogen, oxygen, sulfur and phosphorus, does not contain unsaturation, and is connected to the parent nucleus by a single bond. The heterospirocycle can be optionally substituted. In certain embodiments, the heterospirocycle contains one or more carbonyl or thiocarbonyl groups, such as groups comprising oxo and thio. "7 to 11 membered heterospirocyclyl" refers to a heterospirocyclyl having 7 to 11 ring atoms, wherein 1, 2 or 3 ring atoms are heteroatomic. Non-limiting examples of heterospirocyclyl include 2,6-diazaspiro[3.4]octan-5-onyl, 2-oxo-6-azaspiro[3.3]heptyl, 6-oxaspiro[3.3]heptan-2-yl, 7-methyl-7-azaspiro[3.5]nonan-2-yl, 7-methyl-2,7-diazaspiro[3.5]nonan-2-yl, 9-methyl-9-phosphaspiro[5.5]undecan-3-yl, and the like. a 、R b Together with the connected nitrogen atom, a 7- to 11-membered heterospiro ring is formed, wherein the 7- to 11-membered heterospiro ring is a heterospiro ring that shares a spiro atom and contains 1 or 2 heteroatoms selected from nitrogen and oxygen. The heteroatom "nitrogen" includes R a 、R b connected nitrogen atoms.
[0080] The terms "heterocycloalkenyl" and "heterocycloalkenyl ring" are used interchangeably and refer to a heterocycloalkyl group containing one or more carbon-carbon double bonds or carbon-nitrogen double bonds in the ring, but are not intended to include heteroaryl moieties as defined herein. The group may be fused to an aryl or heteroaryl group. The heterocycloalkenyl ring may be optionally substituted. In certain embodiments, the heterocycloalkenyl ring contains one or more carbonyl or thiocarbonyl groups, such as groups comprising oxo and thio. A "5- to 8-membered heterocycloalkenyl ring" refers to a heterocycloalkenyl ring having 5 to 8 ring atoms, wherein 1, 2 or 3 ring atoms are heteroatoms selected from nitrogen, oxygen and sulfur, such as a 5- to 6-membered heterocycloalkenyl ring. Non-limiting examples of heterocycloalkenyl rings include 4,5-dihydro-1H-imidazole ring, 1,4,5,6-tetrahydropyrimidine ring, 3,4,7,8-tetrahydro-2H-1,4,6-oxadiazolidine ring, 1,6-dihydropyrimidine ring, 4,5,6,7-tetrahydro-1H-1,3-diazepine ring, Cyclic, 2,5,6,7-tetrahydro-1,3,5-oxadiazepine Ring, pyrimidin-2(1H)-one, pyrazin-2(1H)-one, pyridin-2(1H)-one.
[0081] The terms "aryl" and "aromatic ring" are used interchangeably and refer to an all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group having a conjugated π electron system, which may be fused to a cycloalkyl ring, a heterocycloalkyl ring, a cycloalkenyl ring, a heterocycloalkenyl ring, or a heteroaryl ring. 6-10 The term "aryl" refers to a monocyclic or bicyclic aromatic group having 6 to 10 carbon atoms. Non-limiting examples of aryl include phenyl, naphthyl, and the like.
[0082] The terms "heteroaryl" and "heteroaryl ring" are used interchangeably and refer to a group of a monocyclic, bicyclic or polycyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic arrangement) having ring carbon atoms and ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur. In the present application, heteroaryl also includes a ring system in which the above-mentioned heteroaryl ring is fused to one or more cycloalkyl rings, heterocycloalkyl rings, cycloalkenyl rings, heterocycloalkenyl rings or aromatic rings. The heteroaryl ring may be optionally substituted. "5 to 10 membered heteroaryl" refers to a monocyclic or bicyclic heteroaryl group having 5 to 10 ring atoms, wherein 1, 2, 3 or 4 ring atoms are heteroatoms. "5- to 6-membered heteroaryl" refers to a monocyclic heteroaryl group having 5 to 6 ring atoms, wherein 1, 2, 3 or 4 of the ring atoms are heteroatoms, non-limiting examples of which include thienyl, furanyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and tetrazinyl. "8- to 10-membered heteroaryl" refers to a bicyclic heteroaryl group having 8 to 10 ring atoms, wherein 1, 2, 3 or 4 of the ring atoms are heteroatoms, non-limiting examples of which include indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, The term "heteroatom" refers to nitrogen, oxygen, or sulfur. In heteroaryl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, as valence permits. Heteroaryl bicyclic ring systems may include one or more heteroatoms in one or both rings.
[0083] "Fused" refers to structures in which two or more rings share one or more bonds.
[0084] "Benzoheterocycloalkyl" refers to a group in which a benzene ring is fused to a heterocycloalkyl ring to form a bicyclic, tricyclic, or polycyclic ring system, wherein the heterocycloalkyl ring is as defined above. "7- to 11-membered phenylheterocycloalkyl" refers to a bicyclic cyclic group having 7 to 11 ring atoms, of which 1, 2, 3, or 4 are heteroatoms selected from nitrogen, oxygen, and sulfur. For example, an 8- to 10-membered phenylheterocycloalkyl group has 8 to 10 ring atoms, of which 1, 2, or 3 are heteroatoms selected from nitrogen, oxygen, and sulfur. Non-limiting examples include indoline, benzo[d][1,3]dioxazole, 1,2,3,4-tetrahydroisoquinoline, 3,4-dihydro-2H-benzo[b][1,4]oxazine, and the like.
[0085] "Heteroarylheterocycloalkyl" refers to a group in which a heteroaryl ring is fused to a heterocycloalkyl ring to form a bicyclic, tricyclic, or polycyclic ring system, wherein the heterocycloalkyl ring is as defined above. "7- to 11-membered heteroarylheterocycloalkyl" refers to a bicyclic cyclic group having 7 to 11 ring atoms, of which 1, 2, 3, or 4 are heteroatoms selected from nitrogen, oxygen, and sulfur. For example, an 8- to 10-membered heteroarylheterocycloalkyl group has 8 to 10 ring atoms, of which 1, 2, 3, or 4 are heteroatoms selected from nitrogen, oxygen, and sulfur. Non-limiting examples include 2,3-dihydro-1H-pyrrolo[2,3-b]pyridine, [1,3]dioxolane[4,5-b]pyridine, 2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazine, 2,3,4,6-tetrahydropyrrolo[3,4-b][1,4]oxazine, 2,4,5,6-tetrahydropyrano[2,3-c]pyrazole, 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine, and the like.
[0086] "Alkoxy" refers to an -O-alkyl group, wherein alkyl is as defined above, for example, C 1-8 Alkoxy, in some embodiments C 1-6 Alkoxy, in other embodiments, is C 1-3 Alkoxy. Non-limiting examples of alkoxy include methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, tert-butoxy, isobutoxy, pentoxy, and the like.
[0087] "Cycloalkyloxy" refers to an -O-cycloalkyl group, wherein the cycloalkyl group is as defined above. For example, C 3-8 Cycloalkyloxy, in some embodiments C 3-6 Cycloalkyloxy. Non-limiting examples of cycloalkyloxy include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
[0088] "A bond" means that the two groups connected thereto are connected by one covalent bond.
[0089] "Halogen" refers to fluorine, chlorine, bromine or iodine.
[0090] "Halo" refers to a group in which one or more (eg, 1, 2, 3, 4, or 5) hydrogen atoms are replaced by a halogen.
[0091] For example, "haloalkyl" refers to an alkyl group whose hydrogen atoms are replaced by one or more (e.g., 1, 2, 3, 4, or 5) halogen atoms, wherein alkyl is as defined above, for example, a halogenated C 1-8 Alkyl, more preferably halogenated C 1-6 Alkyl, in some embodiments, is halogenated C 1-3 Examples of haloalkyl groups include, but are not limited to, monochloromethyl, dichloromethyl, trichloromethyl, monochloroethyl, 1,2-dichloroethyl, trichloroethyl, monobromoethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, and the like.
[0092] For example, "haloalkoxy" refers to an alkoxy group in which the hydrogen atoms are replaced by one or more (e.g., 1, 2, 3, 4, or 5) halogen atoms, wherein the alkoxy group is as defined above, for example, a halogenated C 1-8 Alkoxy, in some embodiments, is halogenated C 1-6 Alkoxy, in other embodiments, is halogenated C 1-3 Alkoxy. Haloalkoxy includes, but is not limited to, trifluoromethoxy, trifluoroethoxy, monofluoromethoxy, monofluoroethoxy, difluoromethoxy, difluoroethoxy, and the like.
[0093] For example, "halogenated cycloalkyl" refers to a cycloalkyl group whose hydrogen is replaced by one or more (such as 1, 2, 3, 4 or 5) halogens, wherein the cycloalkyl group is as defined above, for example, a halogenated C 3-8 Cycloalkyl, in some embodiments, is a halo-C 3-6 Cycloalkyl. Halocycloalkyl includes, but is not limited to, trifluorocyclopropyl, monofluorocyclopropyl, monofluorocyclohexyl, difluorocyclopropyl, difluorocyclohexyl, and the like.
[0094] "Deuterated alkyl" refers to an alkyl group in which one or more (e.g., 1, 2, 3, 4, or 5) deuterium atoms replace the hydrogen atoms, wherein the alkyl group is as defined above, for example, a deuterated C 1-8 Alkyl, in some embodiments deuterated C 1-6 Alkyl, in other embodiments deuterated C 1-3 Examples of deuterated alkyl groups include, but are not limited to, monodeuterated methyl, monodeuterated ethyl, dideuterated methyl, dideuterated ethyl, trideuterated methyl, trideuterated ethyl, and the like.
[0095] "Amino" refers to NH2, "cyano" refers to CN, "nitro" refers to NO2, "benzyl" refers to -CH2-phenyl, "oxo" refers to =O, "carboxyl" refers to -C(O)OH, "acetyl" refers to -C(O)CH3, "hydroxymethyl" refers to -CH2OH, "hydroxyethyl" refers to -CH2CH2OH or -CHOHCH3, "hydroxy" refers to -OH, "mercapto" refers to SH, and the structure of "cyclopropylene" is:
[0096] "Saturated or partially unsaturated monocyclic ring" refers to a saturated or partially unsaturated all-carbon monocyclic ring system, wherein "partially unsaturated" refers to a ring portion including at least one double bond or triple bond, and "partially unsaturated" is intended to cover rings with multiple unsaturated sites, but is not intended to include aryl or heteroaryl moieties as defined herein. In certain embodiments, the saturated or partially unsaturated monocyclic ring contains one or more carbonyl groups, such as an oxo group. "3 to 7 membered saturated or partially unsaturated monocyclic ring" has 3 to 7 ring carbon atoms, such as a saturated or partially unsaturated monocyclic ring with 3 to 6 ring carbon atoms, and in some embodiments a saturated monocyclic ring with 3 to 6 ring carbon atoms. Non-limiting examples of saturated or partially unsaturated monocyclic rings include cyclopropyl ring, cyclobutyl ring, cyclopentyl ring, cyclopentenyl ring, cyclohexyl ring, cyclohexenyl ring, cyclohexadienyl ring, cycloheptyl ring, cycloheptatrienyl ring, cyclopentanone ring, cyclopentane-1,3-dione ring, etc.
[0097] "Saturated or partially unsaturated monocyclic heterocycle" means a saturated or partially unsaturated monocyclic ring in which one, two or three carbon atoms are selected from nitrogen, oxygen or S(O) t(wherein t is an integer of 0, 1 or 2), excluding the ring portion of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. A "3- to 7-membered saturated or partially unsaturated monocyclic heterocycle" has 3 to 7 ring atoms, of which 1, 2 or 3 ring atoms are the above-mentioned heteroatoms, for example, a 3- to 6-membered saturated or partially unsaturated monocyclic heterocycle having 3 to 6 ring atoms, of which 1 or 2 ring atoms are the above-mentioned heteroatoms, in some embodiments, a 5- to 6-membered saturated or partially unsaturated monocyclic heterocycle having 5 to 6 ring atoms, of which 1 or 2 ring atoms are the above-mentioned heteroatoms, and in other embodiments, a 5- or 6-membered saturated monocyclic heterocycle. Non-limiting examples of saturated monocyclic heterocycles include an oxetane ring, an azetidine ring, an oxetane ring, a tetrahydrofuran ring, a tetrahydrothiophene ring, a tetrahydropyrrole ring, a piperidine ring, a pyrroline ring, an oxazolidine ring, a piperazine ring, a dioxolane ring, a dioxane ring, a morpholine ring, a thiomorpholine ring, a thiomorpholine-1,1-dioxide, a tetrahydropyran ring, an azetidine-2-one ring, an oxetane-2-one ring, a pyrrolidine-2-one ring, a pyrrolidine-2,5-dione ring, a piperidin-2-one ring, a dihydrofuran-2(3H)-one ring, a dihydrofuran-2,5-dione ring, a tetrahydro-2H-pyran-2-one ring, a piperazin-2-one ring, and a morpholine-3-one ring. Non-limiting examples of partially unsaturated monocyclic heterocycles include 1,2-dihydroazetidine ring, 1,2-dihydrooxetadiene ring, 2,5-dihydro-1H-pyrrole ring, 2,5-dihydrofuran ring, 2,3-dihydrofuran ring, 2,3-dihydro-1H-pyrrole ring, 3,4-dihydro-2H-pyran ring, 1,2,3,4-tetrahydropyridine ring, 3,6-dihydro-2H-pyran ring, 1,2,3,6-tetrahydropyridine ring, 4,5-dihydro-1H-imidazole ring, 1,4,5,6-tetrahydropyrimidine ring, 3,4,7,8-tetrahydro-2H-1,4,6-oxadiazolidine ring, 1,6-dihydropyrimidine ring, 4,5,6,7-tetrahydro-1H-1,3-diazepine ring. Cyclic, 2,5,6,7-tetrahydro-1,3,5-oxadiazepine Ring, etc.
[0098] "Substituted" refers to one or more hydrogen atoms in a group, for example, 1 to 5 hydrogen atoms, which are independently replaced by a corresponding number of substituents, and in some embodiments, 1 to 3 hydrogen atoms, which are independently replaced by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (e.g., olefinic) bond.
[0099] Unless otherwise defined, the "substituents independently selected from..." mentioned herein means that when more than one hydrogen on a group is replaced by a substituent, the substituents may be of the same or different types, and the substituents selected are of independent types.
[0100] Unless otherwise defined, the phrase "...same or different, and each independently is..." in this application means that when there are more than one identical substituent group in the general formula, the groups may be the same or different and are each independent species. For example, L is (CR 01 R 02 ) s , when s is 2, that is, L is (CR 01 R 02 )-(CR 01 R 02 ), where two R 01 Can be the same or different, two R 02 They can be the same or different and are independent species. For example, L can be C(CH3)(CN)-C(CH2CH3)(OH), C(CH3)(CN)-C(CH3)(OH) or C(CN)(CH2CH3)-C(OH)(CH2CH3).
[0101] Unless otherwise defined, any group herein may be substituted or unsubstituted. When the above groups are substituted, the substituents may be 1 to 5 groups independently selected from cyano, halogen (such as fluorine or chlorine), C 1-8 Alkyl (such as C 1-6 Alkyl, in some embodiments C 1-3 Alkyl), C 1-8 Alkoxy (e.g. C 1-6 Alkoxy, in some embodiments C 1-3 Alkoxy), halogenated C 1-8 Alkyl (e.g. halo-C 1-6 Alkyl, in some embodiments haloC 1-3 Alkyl), C 3-8 Cycloalkyl (e.g. C 3-6 Cycloalkyl), halogenated C 1-8 Alkoxy (e.g., halo-C 1-6 Alkoxy, in some embodiments haloC 1-3 Alkoxy), C 1-8 Alkyl-substituted amino, halogenated C 1-8 Alkyl-substituted amino, acetyl, hydroxy, hydroxymethyl, hydroxyethyl, carboxyl, nitro, C 6-10 Aryl (e.g. phenyl), C 3-8 Cycloalkyloxy (e.g., C 3-6 Cycloalkyloxy), C 2-8 Alkenyl (e.g. C 2-6Alkenyl, in some embodiments C 2-4 alkenyl), C 2-8 Alkynyl (e.g. C 2-6 Alkynyl, in some embodiments C 2-4 Alkynyl), -CONR a0 R b0 、-C(O)OC 1-10 Alkyl (e.g. -C(O)OC 1-6 Alkyl, in some embodiments -C(O)OC 1-3 alkyl), -CHO, -OC(O)C 1-10 Alkyl (e.g. -OC(O)C 1-6 Alkyl, in some embodiments -OC(O)C 1-3 Alkyl), -SO2C 1-10 Alkyl (e.g. -SO2C 1-6 Alkyl, in some embodiments -SO2C 1-3 Alkyl), -SO2C 6-10 Aryl (e.g., -SO2C6 aryl, in some embodiments, -SO2-phenyl), -COC 6-10 Aryl (e.g., -COC6 aryl, in some embodiments, -CO-phenyl), 4- to 6-membered saturated or unsaturated monocyclic heterocyclic ring, 4- to 6-membered saturated or unsaturated monocyclic ring, 5- to 6-membered monocyclic heteroaryl ring, 8- to 10-membered bicyclic heteroaryl ring, spirocyclic ring, spiroheterocyclic ring, bridged ring, or bridged heterocyclic ring, wherein R a0 、R b0 are each independently hydrogen or C 1-3 alkyl.
[0102] In the present application, when the number of substituents is greater than 1, any two substituents may be the same or different. For example, the substituents may be two halogens that are the same or different, or one halogen and one hydroxyl group.
[0103] Each type of substituent group described herein above can itself be substituted with the groups described herein.
[0104] When the 4- to 6-membered saturated monocyclic heterocycle described herein is substituted, the substituents may be positioned at their possible chemical positions. Representative substitutions of exemplary monocyclic heterocycles are shown below:
[0105] Wherein "Sub" represents various substituents described herein; Indicates the connection position with other atoms.
[0106] Pharmaceutical composition
[0107] Generally, the compounds of the present application or their pharmaceutically acceptable salts or stereoisomers can be administered in a suitable dosage form with one or more pharmaceutical carriers. These dosage forms are suitable for oral, rectal, topical, oral, and other parenteral administrations (e.g., subcutaneous, intramuscular, intravenous, etc.). For example, dosage forms suitable for oral administration include capsules, tablets, granules, and syrups. The compounds of the present application contained in these preparations can be solid powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; water-in-oil or oil-in-water emulsions, etc. The above dosage forms can be prepared from the active compound and one or more carriers or excipients via common pharmaceutical methods. The above carriers need to be compatible with the active compound or other excipients. For solid preparations, commonly used non-toxic carriers include but are not limited to mannitol, lactose, starch, magnesium stearate, cellulose, glucose, sucrose, etc. Carriers for liquid preparations include water, physiological saline, aqueous glucose solution, ethylene glycol, and polyethylene glycol, etc. The active compound can form a solution or suspension with the above carriers.
[0108] "Pharmaceutically acceptable carrier" refers to a non-toxic, inert, solid, semi-solid substance or liquid filler, diluent, encapsulating material or auxiliary formulation or any type of excipient that is compatible with a patient, in some embodiments, a mammal, such as a human, and is suitable for delivering an active agent to a target site without terminating the activity of the agent.
[0109] The "active substance of the present application" or "active compound of the present application" refers to the compound of formula (I) of the present application, or a pharmaceutically acceptable salt, or a solvate, or a stereoisomer, or a prodrug thereof, which has PI3Kγ selective inhibitory activity.
[0110] The compositions of the present application are formulated, dosed and administered in a manner consistent with medical practice. The "therapeutically effective amount" of the compound administered is determined by factors such as the specific condition to be treated, the individual being treated, the cause of the condition, the target of the drug, and the mode of administration.
[0111] "Therapeutically effective amount" refers to the amount of the compound of the present invention that will induce a biological or medical response in a subject, such as reducing or inhibiting enzyme or protein activity or improving symptoms, alleviating symptoms, slowing or delaying disease progression, or preventing disease.
[0112] The therapeutically effective amount of the compound of the present application or its pharmaceutically acceptable salt or stereoisomer thereof contained in the pharmaceutical composition or the pharmaceutical composition of the present application is, for example, 0.1 mg / kg-5 g / kg (body weight).
[0113] "Patient" refers to an animal, preferably a mammal, more preferably a human. The term "mammal" refers to warm-blooded vertebrate mammals, including, for example, cats, dogs, rabbits, bears, foxes, wolves, monkeys, deer, mice, pigs and humans.
[0114] "Treatment" refers to alleviating, slowing the progression of, attenuating, preventing, or maintaining an existing disease or condition (eg, cancer). Treatment also includes curing, preventing the development of, or alleviating to some extent, one or more symptoms of a disease or condition.
[0115] The term "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts. Pharmaceutically acceptable acid addition salts are salts formed with inorganic or organic acids that retain the biological effectiveness of the free base without other side effects. These salts can be prepared by methods known in the art.
[0116] "Pharmaceutically acceptable base addition salts" include, but are not limited to, salts with inorganic bases such as sodium, potassium, calcium, and magnesium salts. They also include, but are not limited to, salts with organic bases such as ammonium, triethylamine, lysine, and arginine salts. These salts can be prepared by methods known in the art.
[0117] When the compound shown in formula (I) of the present application contains one or more chiral centers, it can exist in different optically active forms. When the compound of formula (I) contains one chiral center, the compound contains a pair of enantiomers. The two enantiomers of the compound and the mixture of the pair of enantiomers, such as a racemic mixture, are also within the scope of protection of the present application. Enantiomers can be separated by methods known in the art, such as crystallization and chiral chromatography. When the compound of formula (I) contains more than one chiral center, the compound contains enantiomers and diastereomers. All enantiomers and diastereomers of the compound, as well as mixtures of enantiomers, mixtures of diastereomers, and mixtures of enantiomers and diastereomers are also within the scope of protection of the present application. Enantiomers and diastereomers can be separated by methods known in the art, such as crystallization and preparative chromatography.
[0118] Preparation method
[0119] The application provides a preparation method of a compound of formula (I), which can be synthesized using standard synthesis techniques known to those skilled in the art or using methods known in the art in combination with the methods described herein. The solvent, temperature, and other reaction conditions provided herein can be changed according to the art. The reactions can be used in sequence to provide compounds of the application, or they can be used to synthesize fragments, which are subsequently added by methods described herein and / or methods known in the art.
[0120] The compound described in this application can use the illustrative method described in the following similar method or embodiment, or the relevant open literature used by those skilled in the art, by using appropriate selectable starting material synthetic compound.The starting material for synthesizing the compound described in this application can be synthesized or can be obtained from commercial sources.The compound described in this application and other related compounds with different substituents can be synthesized using technology and raw materials known to those skilled in the art.The general method for preparing compounds disclosed in this application can be from reaction known in the art, and the reaction can be modified by those skilled in the art to consider appropriate reagents and conditions to introduce the various parts in the molecule provided by the application.
[0121] The main advantages of this application include:
[0122] Provides a series of six-membered aromatic ring pyrrolidine derivatives, which have high selective inhibitory activity against PI3Kγ and improved in vivo pharmacokinetic parameters, and the inhibitory activity IC of PI3Kγ kinase is 50 values less than 100 nM, and in some embodiments have an IC less than 50 nM 50 values, in some embodiments having an IC of less than 10 nM 50 The present invention has the advantages of good molecular weight, and thus can be used as a drug for treating and / or preventing diseases associated with PI3Kγ activity or mediated by PI3Kγ activity.
[0123] The present application will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present application only and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are generally based on conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight. Unless otherwise defined, the terms used herein have the same meaning as those familiar to those skilled in the art. In addition, any method and material similar or equivalent to the described content can be applied to the present application.
[0124] Known starting materials can be synthesized by methods known in the art, or can be purchased from companies such as ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, and Darui Chemicals.
[0125] Unless otherwise specified, the reactions in the examples were carried out under nitrogen or argon atmosphere.
[0126] DCM: dichloromethane, TEA: triethylamine, Et3N: triethylamine, DIPEA: N,N-diisopropylethylamine, NaOH: sodium hydroxide, K2CO3: potassium carbonate, CCl4: carbon tetrachloride, ACN: acetonitrile, CH3CN: acetonitrile, MeCN: acetonitrile, n-BuLi: n-butyllithium, CDCl3: deuterated chloroform, CuBr2: copper bromide, Pd / C: palladium / carbon, H2O: water, CuI: cuprous iodide, t-BuONO: tert-butyl nitrosoate, HCl: hydrogen chloride, TsOH: p-toluenesulfonic acid, N2H4·H2O: hydrazine hydrate, POCl3: Phosphorus oxychloride, H2: hydrogen, N2: nitrogen, NH4HCO3: ammonium bicarbonate, Cs2CO3: cesium carbonate, NH3.H2O: ammonia water, MeOH: methanol, DAST: diethylaminosulfur trifluoride, CO: carbon monoxide, LiOH: lithium hydroxide, TFA: trifluoroacetic acid, NaHMDS: sodium bis(trimethylsilyl)amide, DMF: dimethylformamide, DMSO: dimethyl sulfoxide, DMSO-d6: deuterated dimethyl sulfoxide THF: tetrahydrofuran, DIEA: N,N-diisopropylethylamine, EA: ethyl acetate, EtOAc: ethyl acetate; PE: petroleum ether, DMAP: 4-dimethylaminopyridine, TsCl: 4-toluenesulfonyl chloride, HATU: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, DMF-DMA: N,N-dimethylformamide dimethyl acetal, LDA: lithium diisopropylamide, MCPBA: m-chloroperbenzoic acid, TMSCN: trimethylsilyl cyanide, TMSCl: trimethylchlorosilane, BINAP: (2R,3S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, NBS: N-bromosuccinimide, NCS: N-chlorosuccinimide, Pd2( dba)3: tris(dibenzylideneacetone)dipalladium, Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, Pd(dppf)Cl2: [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride, PdCl2(dppf): [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride, Pd(PPh3)2Cl2: bis(triphenylphosphine)palladium(II) chloride, DPPA: diphenylphosphoryl azide, Selectfluor: 1-chloromethyl-4-fluoro-1,4-diazobicyclo[2.2.2]octane bis(tetrafluoroborate). (t-Bu)3PHBF4: tri-tert-butylphosphine tetrafluoroborate, TLC: thin layer chromatography, MeMgBr: methylmagnesium bromide, NaI: sodium iodide, K2OsO4: potassium osmate, BAST: 2-methoxy-N-(2-methoxyethyl)-N-(trifluorosulfonyl)ethylamine, Zn(CN)2: zinc cyanide.
[0127] Unless otherwise specified, the percentage contents mentioned in this application refer to mass percentage for solid-liquid mixture and solid-solid mixture, and refer to volume percentage for liquid-liquid mixture.
[0128] As used herein, room temperature refers to about 20-30°C.
[0129] Preparation of intermediate 1
[0130] Dissolve N-(4-methylthiazol-2-yl)acetamide (500 mg, 3.20 mmol) in acetic acid (15 mL). Add NBS (854.57 mg, 4.80 mmol) with stirring at room temperature and stir overnight. LC-MS analysis revealed the desired product. The reaction mixture was poured into water, extracted with ethyl acetate (30 mL x 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified on a silica gel column (EA:PE = 0-50%) to afford Intermediate 1 (450 mg, 1.91 mmol, 59.80% yield) as a white solid. MS (ESI): 235.2 [M+H] + .
[0131] Preparation of intermediate 2
[0132] Step 1: Dissolve 4-chloro-2-methylbenzoic acid (30 g, 175.86 mmol), palladium acetate (1.97 g, 8.79 mmol), iodophenyldiacetic acid (113.29 g, 351.71 mmol), and iodine (66.95 g, 263.79 mmol) in DMF (300 mL). Heat to 100°C and react overnight under nitrogen. Cool the mixture to room temperature, quench with saturated sodium thiosulfate solution, and extract with ethyl acetate. The extract is washed with 10% NaOH solution, and the aqueous phase is acidified and extracted with ethyl acetate. Wash twice with saturated brine, dry over anhydrous sodium sulfate, and spin-dry to obtain the crude product, 4-chloro-2-iodo-6-methylbenzoic acid (43 g, 82.47% yield), as a brown oil.
[0133] Step 2: Dissolve 4-chloro-2-iodo-6-methylbenzoic acid (35 g, 118.05 mmol) and iodomethane (30.16 g, 212.49 mmol) in DMF (60 mL). Add potassium carbonate (32.63 g, 236.10 mmol) and react at room temperature for 2 hours. Dilute with water (300 mL) and extract with ethyl acetate (200 mL). Wash the organic phase twice with saturated brine, dry over anhydrous sodium sulfate, and spin dry to obtain the crude product. The crude product was separated by a Combiflash column (80 g, 0-50% PE / EtOAc) to obtain methyl 4-chloro-2-iodo-6-methylbenzoate (22 g, 60.02% yield).
[0134] Step 3: Methyl 4-chloro-2-iodo-6-methylbenzoate (22 g, 70.85 mmol), N-bromosuccinimide (22.70 g, 127.53 mmol), and azobisisobutyronitrile (1.16 g, 7.09 mmol) were dissolved in carbon tetrachloride (300 mL), heated to 90°C, and reacted for 24 hours. Saturated sodium bisulfite was added to the system, diluted with water, extracted with dichloromethane, and the organic phase was washed twice with saturated brine, dried over anhydrous sodium sulfate, and spin-dried to obtain the crude product. The crude product was separated by Combiflash column (0-80% EA / PE) to obtain methyl 2-(bromomethyl)-4-chloro-6-iodobenzoate (25 g, yield 90.61%) as a yellow oil. MS (ESI): 388.7 [M+H] + .
[0135] Step 4: Methyl 2-(bromomethyl)-4-chloro-6-iodobenzoate (25 g, 64.20 mmol) was dissolved in acetonitrile (120 mL). (S)-1-cyclopropylethylamine hydrochloride (7.81 g, 64.20 mmol) was added to the reaction mixture at room temperature. Boric acid (4.76 g, 77.04 mmol) was then added to the reaction mixture. Finally, potassium carbonate (17.75 g, 128.40 mmol) was added portionwise to the reaction mixture. The mixture was stirred at 40°C for 20 h. The reaction mixture was filtered, the filtrate was washed with acetonitrile, and the organic phase was dried. The crude product was purified by Combiflash column chromatography (4 g, 0-50% PE / EtOAc) to afford Intermediate 2 (9.5 g, 40.92% yield) as a pale yellow solid. MS (ESI): 361.9 [M+H] + .
[0136] Preparation of intermediate 3
[0137] Step 1: Dissolve (S)-1-cyclopropylethane-1-amine hydrochloride (4.5 g, 37.00 mmol) and 4-chloro-2-(trifluoromethyl)benzoic acid (9.14 g, 40.70 mmol) in DMF (40 mL). Then add DIPEA (14.35 g, 111.01 mmol, 19.34 mL) and HATU (27.92 g, 74.01 mmol). Stir the reaction at 21°C for 4 hours. After completion, pour the reaction mixture into saturated aqueous ammonium chloride, extract three times with ethyl acetate, wash once with saturated aqueous sodium bicarbonate, and wash the organic phase twice with saturated brine. Dry over anhydrous sodium sulfate, and evaporate the solvent under reduced pressure to obtain the crude product. Separate the product by passing it through a Combiflash column (80 g, 0-40% EA / PE). The white solid product (S)-4-chloro-N-(1-cyclopropylethyl)-2-(trifluoromethyl)benzamide (9.8 g, 91%) was successfully obtained. MS (ESI): 292.1 [M+H] + .
[0138] Step 2: Dissolve (S)-4-chloro-N-(1-cyclopropylethyl)-2-(trifluoromethyl)benzamide (8.8 g, 30.17 mmol) in THF (100 mL). Lower the reaction temperature to -78°C, then add sec-butyllithium (1.3 M, 58.02 mL) dropwise over approximately 20 minutes. Stir for 10 minutes, then add DMF (11.03 g, 150.84 mmol) dropwise at this temperature. Stir the reaction at this temperature for 1.5 hours. After completion of the reaction, slowly add saturated aqueous ammonium chloride to the reaction mixture at low temperature. Extract three times with ethyl acetate, dry over anhydrous sodium sulfate, filter, and evaporate the solvent under reduced pressure to obtain 5-chloro-2-((S)-1-cyclopropylethyl)-3-hydroxy-7-(trifluoromethyl)isoindol-1-one (12.1 g, 100.00%) as a pale yellow solid. MS(ESI):320.1[M+H] + .
[0139] Step 3: Dissolve 5-chloro-2-((S)-1-cyclopropylethyl)-3-hydroxy-7-(trifluoromethyl)isoindol-1-one (12.1 g, 37.85 mmol) in DCM (130 mL), then lower the temperature to 0°C and add triethylsilane (4.40 g, 37.85 mmol, 6.04 mL) and TFA (87.50 g, 767.35 mmol, 57 mL) in sequence. The reaction mixture was allowed to warm to room temperature and stirred for 0.5 hours. After completion of the reaction, the reaction mixture was concentrated, neutralized with saturated sodium bicarbonate, extracted with dichloromethane, and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Combiflash (0-30%, ethyl acetate / petroleum ether) was used to separate the product, (S)-5-chloro-2-(1-cyclopropylethyl)-7-(trifluoromethyl)isoindol-1-one (8.9 g, 77%), which was a yellow solid. MS (ESI): 304.1 [M+H] + .
[0140] Step 4: (S)-5-chloro-2-(1-cyclopropylethyl)-7-(trifluoromethyl)isoindol-1-one (5.15 g, 16.96 mmol) was dissolved in dioxane (85 mL), and then pinacol biboronate (4.74 g, 18.67 mmol), potassium acetate (5.83 g, 59.40 mmol), and chloro[(tricyclohexylphosphine)-2-(2-aminobiphenyl)]palladium(II) (999.63 mg, 1.70 mmol) were added. The reaction was stirred at 100°C for 1 hour. After the reaction was complete, the mixture was cooled to room temperature, filtered, and the filtrate was concentrated to obtain the crude product. Combiflash (0-40%, ethyl acetate / petroleum ether) was used for separation. Intermediate 3 (6.1 g, 91%) was obtained as a pale yellow solid. MS (ESI): 396.2 [M+H] + .
[0141] Preparation of intermediate 4
[0142] Step 1: Dissolve 4-bromo-2-fluoro-6-methylbenzoic acid (15 g, 64.37 mmol) in DMF (107 mL), then add K2CO3 (26.72 g, 193.30 mmol) and iodomethane (18.28 g, 128.76 mmol, 8 mL). The reaction is stirred at 80°C for 1 hour. After completion, cool to room temperature (20°C), quench with 500 mL of aqueous solution, and extract three times with ethyl acetate. The organic phase is washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the solvent is evaporated under reduced pressure to obtain the crude product. Separate the product by Combiflash column (8 g, 0-20% EA / PE). Methyl 4-bromo-2-fluoro-6-methylbenzoate (12.7 g, 80%) is obtained as a colorless oil. MS (ESI): 247 [M+H] + .
[0143] Step 2: Methyl 4-bromo-2-fluoro-6-methylbenzoate (12.7 g, 51.40 mmol) was dissolved in CCl4 (322 mL), and then NBS (18.30 g, 102.81 mmol) and benzoyl peroxide (794.45 mg, 10.28 mmol, 80% purity) were added. The reaction was stirred at 90°C for 18 hours. After completion of the reaction, the mixture was cooled to room temperature, quenched with aqueous solution, extracted with solvent, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and dried under reduced pressure to give the crude product, methyl 4-bromo-2-(dibromomethyl)-6-fluorobenzoate (21.5 g, 103% yield), as a pale yellow oil. MS (ESI): 405 [M+H] + .
[0144] Step 3: Dissolve methyl 4-bromo-2-(dibromomethyl)-6-fluorobenzoate (21.5 g, 53.11 mmol) in ACN (200 mL), cool to 0-5°C, add DIPEA (6.86 g, 53.11 mmol, 9.25 mL) and diethyl phosphite (5.10 g, 37.17 mmol) dropwise, and react at 0-5°C for 0.5 h. Add saturated sodium bicarbonate at 0-5°C, dilute with water, and extract with ethyl acetate. The organic phase is washed twice with saturated brine, dried over anhydrous sodium sulfate, and spin-dried to obtain the crude product. Ombiflash column separation (120 g, 0-50% PE / EtOAc) successfully afforded methyl 4-bromo-2-(bromomethyl)-6-fluorobenzoate (12.9 g, 74.0%) as a pale yellow oil. MS (ESI): 825 [M+H] + .
[0145] Step 4: (S)-1-Cyclopropylethane-1-amine hydrochloride (4.80 g, 39.48 mmol) was added to CH3CN (250 mL), followed by K2CO3 (24.80 g, 179.47 mmol) and stirred for 5 minutes. Boric acid (2.44 g, 39.48 mmol) and methyl 4-bromo-2-(bromomethyl)-6-fluorobenzoate (11.7 g, 35.89 mmol) dissolved in CH3CN (250 mL) were then added to the reaction mixture and stirred at room temperature for 20 hours. Water was added and the mixture was extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The product was separated by Combiflash column (40 g, 0-20% EA / PE). Intermediate 4 (7.1 g, 66 g) was obtained as a white solid. MS (ESI): 298 [M+H] + .
[0146] Preparation of intermediate 5
[0147] Step 1: Dissolve 2,6-dichloro-4-methylnicotinic acid (40.00 g, 194.15 mmol) and potassium carbonate (67.08 g, 485.38 mmol) in DMF (200 mL). Add iodomethane (41.34 g, 291.23 mmol) dropwise at room temperature. React at 24°C for 1 hour. Pour the reaction solution into water and extract with ethyl acetate. Wash the organic phase twice with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate to obtain a brown crude product, methyl 2,6-dichloro-4-methylnicotinate (39.00 g, 91.29%). MS (ESI): 220.0 [M+H] + .
[0148] Step 2: Dissolve the crude product, methyl 2,6-dichloro-4-methylnicotinate (39.00 g, 177.23 mmol), N-bromosuccinimide (47.32 g, 265.85 mmol), and benzoyl peroxide (47.32 g, 265.85 mmol) in CCl4 (300 mL). The reaction temperature is then raised to 90°C and stirred at 90°C for 48 hours. Water is added, the mixture is extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated to obtain the crude product. Combiflash (0-30%, ethyl acetate / petroleum ether) is used to successfully obtain a mixture of methyl 4-(bromomethyl)-2,6-dichloronicotinate and methyl 2,6-dichloro-4-(dibromomethyl)nicotinate (50 g) as a yellow oil. MS (ESI): 299.8 [M+H] + ,MS(ESI):379.7[M+H] + .
[0149] Step 3: A mixture of the crude products, methyl 4-(bromomethyl)-2,6-dichloronicotinate and methyl 2,6-dichloro-4-(dibromomethyl)nicotinate (50 g), was dissolved in ACN (300 mL) and cooled to 5°C under N2 protection. N,N-diisopropylethylamine (34.20 g, 264.66 mmol) was added dropwise at this temperature, followed by diethyl phosphite (18.14 g, 132.33 mmol). The reaction was allowed to proceed at 5°C for 0.5 h. Once the reaction was complete, saturated aqueous sodium bicarbonate was added, and the mixture was extracted with ethyl acetate. The mixture was washed twice with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and separated using combiflash (0-20%, ethyl acetate / petroleum ether). 4-(bromomethyl)-2,6-dichloronicotinate (28.00 g, 70.78%) was obtained as a yellow oil. MS (ESI): 299.9 [M+H] + .
[0150] Step 4: Methyl (bromomethyl)-2,6-dichloronicotinate (28.00 g, 93.66 mmol) and (S)-1-cyclopropylethylamine hydrochloride (11.39 g, 93.66 mmol) were dissolved in acetonitrile (200 mL), and then boric acid (5.79 g, 93.66 mmol) and potassium carbonate (25.89 g, 187.32 mmol) were added. The reaction was stirred at 24 ° C for 12 hours. The suspension was filtered and the filtrate was dried to obtain the crude product. Combiflash (0-50%, ethyl acetate / petroleum ether) was used for separation to obtain the white solid product intermediate 5 (22.60 g, 88.99%). MS (ESI): 271.0 [M+H] +;
[0151] Preparation of intermediate 6
[0152] n-BuLi (2.5M in THF, 5.12 mL, 12.8 mmol) was added dropwise to a solution of diisopropylamine (1.29 g, 12.8 mmol) in THF (20 mL) at 0°C, and the reaction was maintained at 0°C for 30 minutes. This solution was then slowly added dropwise to a solution of N-(4-methylthiazol-2-yl)acetamide (500 mg, 3.2 mmol) in THF (5 mL) at -78°C, and the reaction continued for 30 minutes. 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.19 g, 6.4 mmol) was slowly added dropwise to the reaction mixture, and the reaction was maintained at -78°C for two hours. The reaction was quenched with saturated ammonium chloride solution, extracted with ethyl acetate, and the organic phase washed twice with brine, dried over sodium sulfate, filtered, and concentrated to afford Intermediate 6 (410 mg, 45% yield) as a pale yellow solid. 1H-NMR (400MHz, CDCl3) δ2.53 (s, 3H), 2.25 (d, J = 2.4Hz, 3H), 1.25 (s, 12H).
[0153] Preparation of intermediate 7
[0154] Step 1: Intermediate 4 (500 mg, 1.68 mmol) and (4-methoxyphenyl)methanamine (690.15 mg, 5.03 mmol) were dissolved in dioxane (10 mL), and potassium carbonate (695.31 mg, 5.03 mmol) was added. The reaction was stirred in a microwave oven at 150°C for 2 hours. The solvent was evaporated under reduced pressure, and the crude product was separated by Combiflash column (0-70% EA / PE) to afford (S)-5-bromo-2-(1-cyclopropylethyl)-7-((4-methoxybenzyl)amino)isoindolin-1-one (650 mg, 93.32% yield) as a yellow solid. MS (ESI): 415.1 [M+H] + .
[0155] Step 2: (S)-5-Bromo-2-(1-cyclopropylethyl)-7-((4-methoxybenzyl)amino)isoindolin-1-one (1.3 g, 3.13 mmol) was dissolved in trifluoroacetic acid (20 mL). The reaction was stirred at 20°C for 20 hours. The solvent was evaporated under reduced pressure and neutralized to alkalinity by adding saturated sodium bicarbonate. The mixture was extracted with DCM and dried over anhydrous sodium sulfate. The solvent was evaporated to dryness. The crude product was separated by combiflash (0-80% EA / PE) to afford intermediate 7 (920 mg, 99.58% yield) as a yellow solid. MS (ESI): 295.1 [M+H] + .
[0156] Preparation of intermediate 8
[0157] Step 1: Dissolve tert-butyl 3-bromo-4-oxopiperidine-1-carboxylate (25 g, 89.88 mmol), thiourea (7.54 g, 99.00 mmol), and DIPEA (27.29 g, 269.65 mmol, 37.61 mL) in DMF (220 mL) and heat to 110°C. Stir the reaction at 110°C for 12 hours. After the reaction is complete, cool the reaction mixture to room temperature and pour it into water (1000 mL). Filter the solid and wash it with a small amount of water. Dry the solid in vacuo to obtain the crude product, tert-butyl 2-amino-6,7-dihydrothiazolo[4,5-c]pyridine-5(4H)-carboxylate (17 g, 74%), as a yellow solid. MS (ESI): 256.1 [M+H] + .
[0158] Step 2: Dissolve tert-butyl 2-amino-6,7-dihydrothiazolo[4,5-c]pyridine-5(4H)-carboxylate (6 g, 23.50 mmol) and tert-butyl nitrite (2.91 g, 28.20 mmol) in CH3CN (50 mL), cool to 0°C, add CuBr2 (6.31 g, 11.53 mmol) to the reaction solution, and stir at 0°C for 2 hours. After the reaction of the raw materials is complete, the reaction solution is diluted with DCM, filtered, and the filtrate is concentrated. The crude product is separated by combiflash (24 g, 0-50% PE / EtOAc) to obtain tert-butyl 2-bromo-6,7-dihydrothiazolo[4,5-c]pyridine-5(4H)-carboxylate (2.2 g, 29%) as a light yellow solid. MS (ESI): 318.9 [M+H] + .
[0159] Step 3: Dissolve tert-butyl 2-bromo-6,7-dihydrothiazolo[4,5-c]pyridine-5(4H)-carboxylate (2.2 g, 6.89 mmol), Pd / C (502 mg, 50% H2O), and potassium hydroxide (541 mg, 9.65 mmol) in methanol (40 mL). The reaction was stirred at 50°C for 3 hours. After the reaction of the raw materials was completed, the reaction solution was filtered and concentrated. The crude product was separated by combiflash (24 g, 0-30% PE / EtOAc) to successfully obtain tert-butyl 6,7-dihydrothiazolo[4,5-c]pyridine-5(4H)-carboxylate (521 mg, 31%) as a light yellow solid. MS (ESI): 241.1 [M+H] + .
[0160] Step 4: tert-Butyl 6,7-dihydrothiazolo[4,5-c]pyridine-5(4H)-carboxylate (521 mg, 2.17 mmol) was dissolved in EA (10 mL), and then hydrogen chloride (4 M in EA, 5.42 mL) was added. The reaction was stirred at room temperature for 3 hours. After the reaction was complete, the reaction solution was concentrated to give the crude product 8 (383 mg, 100.00%) as a pale yellow solid. MS (ESI): 141.1 [M+H] + .
[0161] Preparation of intermediate 9
[0162] Step 1: Dissolve tert-butyl 3,3-difluoro-4-oxo-piperidine-1-carboxylate (4.7 g, 19.98 mmol) and cyanamide (1.68 g, 39.96 mmol) in pyridine (2 mL). Add sulfur (1.28 g, 39.96 mmol). Heat the mixture to 130°C and stir for 1.5 hours. After the reaction is complete, pour the reaction mixture into water and extract with EA. The combined organic phases are dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated and separated by combiflash (40 g, 0-50% PE / EtOAc) to obtain tert-butyl 2-amino-7,7-difluoro-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (5.82 g, 100%) as a yellow solid. MS (ESI): 292 [M+H] + .
[0163] Step 2: Dissolve tert-butyl 2-amino-7,7-difluoro-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (2.8 g, 9.61 mmol) and tert-butyl nitrite (1.19 g, 11.53 mmol) in CH3CN (30 mL), cool to 0°C, add CuBr2 (2.58 g, 11.53 mmol), and stir at 0°C for 2 hours. After the reaction is complete, the reaction mixture is diluted with DCM, filtered, and the filtrate concentrated. The crude product is separated by combiflash (24 g, 0-50% PE / EtOAc) to obtain tert-butyl 2-bromo-7,7-difluoro-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (2.12 g, 62%) as a pale yellow solid. MS(ESI):354.9[M+H] + .
[0164] Step 3: Dissolve tert-butyl 2-bromo-7,7-difluoro-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (2.8 g, 7.88 mmol), Pd / C (957 mg, 50% H2O), and potassium hydroxide (619 mg, 11.04 mmol) in methanol (70 mL). The reaction is stirred at 35°C for 18 hours. After the reaction is complete, the reaction solution is filtered and concentrated. The crude product is separated by combiflash (24 g, 0-30% PE / EtOAc) to obtain tert-butyl 7,7-difluoro-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (800 mg, 37%) as a white solid. MS (ESI): 277.0 [M+H] + .
[0165] Step 4: Dissolve tert-butyl 7,7-difluoro-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (800 mg, 2.90 mmol) in EA (10 mL), then add hydrogen chloride (4 M in EA, 14.48 mL). The reaction is stirred at room temperature for 3 hours. After the reaction is complete, the reaction mixture is concentrated to give the crude product 9 (510 mg, 100%) as a white solid. MS (ESI): 177.1 [M+H] + .
[0166] Preparation of intermediate 10
[0167] Step 1: Dissolve tert-butyl 2-amino-6,7-dihydro-5(4H)-thiazolo[4,5-c]pyridine-5-carboxylate (500 mg, 1.96 mmol) in DCM (10 mL), then add Et3N (1.39 g, 13.71 mmol). Add acetyl chloride (307.43 mg, 3.92 mmol) dropwise at room temperature. After the addition is complete, stir at 20°C for 5 hours. After completion, the reaction is quenched with saturated aqueous sodium bicarbonate, extracted with DCM, and the organic phase is washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent is evaporated under reduced pressure to obtain the crude product. Combiflash (12 g, 0-70% EA / PE) is used for separation and purification. Tert-butyl 2-acetamido-6,7-dihydro-5(4H)-thiazolo[4,5-c]pyridine-5-carboxylate (450 mg, 77%) is obtained as a pale yellow solid. MS(ESI):298.1[M+H] + .
[0168] Step 2: Dissolve tert-butyl 2-acetylamino-6,7-dihydro-5(4H)-thiazolo[4,5-c]pyridine-5-carboxylate (450 mg, 1.52 mmol) in EA (10 mL), then add hydrogen chloride (4 M in EA, 10 mL). The reaction is stirred at room temperature for 3 hours. After the reaction is complete, the reaction mixture is concentrated to give the crude product 10 (353 mg, 100%) as a white solid. MS (ESI): 198.1 [M+H] + .
[0169] Preparation of intermediate 11
[0170] Step 1: Dissolve tert-butyl 2-bromo-6,7-dihydro-5(4H)-thiazolo[4,5-c]pyridine-5-carboxylate (500 mg, 1.57 mmol) in DMF (6 mL), then add CuI (596.62 mg, 3.13 mmol) and methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (902.74 mg, 4.70 mmol). The reaction is stirred at 100°C for 2 hours. After the starting materials react, the reaction solution is diluted with dichloromethane, filtered to remove insoluble material, and the filtrate is concentrated to obtain the crude product. Combiflash (24 g, 0-20% EA / PE) is used for separation and purification. The resulting product, tert-butyl 2-(trifluoromethyl)-6,7-dihydrothiazolo[4,5-c]pyridine-5(4H)-carboxylate (320 mg, 56%), is obtained as an oil. MS(ESI):309.1[M+H] + .
[0171] Step 2: Dissolve tert-butyl 2-(trifluoromethyl)-6,7-dihydrothiazolo[4,5-c]pyridine-5(4H)-carboxylate (320 mg, 1.04 mmol) in EA (10 mL), then add hydrogen chloride (4 M in EA, 10 mL). The reaction is stirred at room temperature for 3 hours. After the reaction is complete, the reaction mixture is concentrated to give the crude product 11 (254 mg, 100%) as a white solid. MS (ESI): 209.1 [M+H] + .
[0172] Preparation of intermediate 12
[0173] Step 1: Dissolve tert-butyl 2-amino-6,7-dihydro-5(4H)-thiazolo[4,5-c]pyridine-5-carboxylate (2500 mg, 9.79 mmol) in MeCN (250 mL), then add cuprous cyanide (1.83 g, 19.58 mmol) and t-BuONO (2.02 g, 19.58 mmol). The reaction was allowed to proceed at room temperature for 1 hour, then heated under reflux with stirring for 6 hours. After cooling to room temperature, the reaction solution was concentrated, diluted with ethyl acetate and water, and insoluble material was removed by filtration. The aqueous phase was extracted with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated to yield the crude product. Combiflash (12 g, 0%-40% EA / PE) was used for separation and purification. Tert-butyl 2-cyano-6,7-dihydrothiazolo[4,5-c]pyridine-5(4H)-carboxylate (700 mg, 27%) was obtained as a pale yellow solid. MS(ESI):266.1[M+H] + .
[0174] Step 2: Dissolve tert-butyl 2-cyano-6,7-dihydrothiazolo[4,5-c]pyridine-5(4H)-carboxylate (300 mg, 1.13 mmol) in EA (10 mL), then add hydrogen chloride (4 M in EA, 10 mL). The reaction is stirred at room temperature for 3 hours. After the reaction is complete, the reaction mixture is concentrated to give the crude product 12 (228 mg, 100%) as a white solid. MS (ESI): 166.1 [M+H] + .
[0175] Preparation of intermediate 13
[0176] Step 1: Dissolve tert-butyl 2-bromo-6,7-dihydro-5(4H)-thiazolo[4,5-c]pyridine-5-carboxylate (800 mg, 2.51 mmol) in THF (10 mL), and then add sodium thiomethoxide (1.08 g, 15.04 mmol). The reaction was stirred at 50°C in a microwave for 4 hours. Aqueous sodium hypochlorite solution was added, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. Combiflash (12 g, 0%-30% EA / PE) was used for separation and purification. tert-butyl 2-methylsulfanyl-6,7-dihydro-5(4H)-thiazolo[4,5-c]pyridine-5-carboxylate (500 mg, 70%) was successfully obtained as a light yellow oil. MS (ESI): 287.1 [M+H] + .
[0177] Step 2: Dissolve tert-butyl 2-methylsulfanyl-6,7-dihydro-5(4H)-thiazolo[4,5-c]pyridine-5-carboxylate (500 mg, 1.75 mmol) in EA (10 mL), then add HCl (4 M, 10 mL). The reaction was stirred at room temperature for 3 hours. After the reaction was complete, the reaction mixture was concentrated to give the crude product, Intermediate 13, as a white solid (353 mg, 100%). MS (ESI): 187.1 [M+H]. + .
[0178] Preparation of intermediate 14
[0179] Dissolve tert-butyl N-(4-methylthiazol-2-yl)carbamate (1 g, 4.67 mmol) in tetrahydrofuran (15 mL), cool to -78°C, and add lithium diisopropylamide (2 M, 7.00 mL) dropwise. Allow to react for 1 h. Then, add tributyltin chloride (1.52 g, 4.67 mmol) and allow to react at -78°C for 1 h. LCMS indicates the reaction is complete. Extract the mixture with water and ethyl acetate, and the organic phase is dried to give the crude product. The crude product is purified by column chromatography to give Intermediate 14 (1.5 g, 2.98 mmol, 63.86% yield) as a yellow oil. MS (ESI): 505 [M+H] + .
[0180] Preparation of intermediate 15
[0181] Step 1: Dissolve tert-butyl 3-oxopiperidine-1-carboxylate (26 g, 130 mmol), tetrahydropyrrole (11.05 g, 156 mmol), and p-toluenesulfonic acid monohydrate (0.78 g, 3.9 mmol) in 150 mL of anhydrous toluene. Heat the mixture to reflux, removing the generated water via a water separator. After 3 hours of reaction, cool the mixture to room temperature and proceed directly to the next step.
[0182] Step 2: To the system of step 1, p-toluenesulfonic acid monohydrate (0.78 g, 3.9 mmol) and ethyl glyoxylate (50% toluene solution) (29.12 mL, 143 mmol) were added. The system was heated to reflux. The reaction was stopped after two hours. The system was cooled to room temperature, concentrated, and separated by column chromatography to obtain the products tert-butyl 2-oxo-4,5-dihydrofuro[2,3-c]pyridine-6(2H)-carboxylate (12.6 g) and tert-butyl (E)-4-(2-ethoxy-2-oxoethylidene)-5-pyrrolidin-1-yl)-3,4-dihydropyridine-1(2H)-carboxylate (3.8 g).
[0183] Step 3: (1) Dissolve tert-butyl 2-oxo-4,5-dihydrofuran[2,3-c]pyridine-6(2H)-carboxylate (12.6 g, 53.11 mmol) in 54 mL of anhydrous ethanol, then add hydrazine hydrate (5.7 g, 91.2 mmol, 80%) and acetic acid (13.5 mL) to the system, heat under reflux for 16 hours, and concentrate the reaction mixture.
[0184] (2) Tert-butyl (E)-4-(2-ethoxy-2-oxoethylidene)-5-pyrrolidin-1-yl)-3,4-dihydropyridine-1(2H)-carboxylate (3.8 g, 11.30 mmol) was dissolved in 11 mL of anhydrous ethanol. Hydrazine hydrate (11.8 g, 188.8 mmol, 80%) and acetic acid (3 mL) were then added to the system. The mixture was heated under reflux for 8 hours, and the mixture was concentrated.
[0185] The concentrated solutions from (1) and (2) were combined and purified by column chromatography to obtain tert-butyl 3-oxo-2,5,6,8-tetrahydropyrido[3,4-c]pyridazine-7(3H)-carboxylate (638 mg, white solid). Yield: 3.67%. MS (ESI): 252.2 / 503.3 [M+H] + .
[0186] Step 4: Dissolve tert-butyl 3-oxo-2,5,6,8-tetrahydropyrido[3,4-c]pyridazine-7(3H)-carboxylate (50 mg, 0.2 mmol) in phosphorus oxychloride (3 mL) under nitrogen protection and react at 100°C for 1 hour. The reaction solution was directly drained to obtain 3-chloro-5,6,7,8-tetrahydropyrido[3,4-c]pyridazine (80 mg). The product was used directly in the next reaction. MS (ESI): 170.2 [M+H] + .
[0187] Step 5: Dissolve 3-chloro-5,6,7,8-tetrahydropyrido[3,4-c]pyridazine (330 mg, 1.95 mmol) in ethyl acetate (10 ml), then add Pd / C (33 mg). The reaction mixture is reacted under a H2 atmosphere at room temperature and atmospheric pressure for 30 hours. Filter and concentrate the filtrate to obtain 5,6,7,8-tetrahydropyrido[3,4-c]pyridazine (Intermediate 15, 200 mg, colorless oil). MS (ESI): 136.2 [M+H] + .
[0188] Preparation of intermediate 16
[0189] Step 1: Dissolve tert-butyl N-(4-methylthiazol-2-yl)carbamate (3.4 g, 15.87 mmol) in tetrahydrofuran (50 mL) and cool to -78°C under argon. Add lithium diisopropylamide (2.0 M, 31.73 mL) dropwise. Stir at -78°C for 2 hours. Add 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (5.90 g, 31.73 mmol) dropwise, and continue stirring at -78°C for 2 hours. The reaction mixture is poured into water, extracted with ethyl acetate (30 mL x 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified on a silica gel column to afford Intermediate 16 (1.2 g, white solid) in a yield of 75.58%. MS (ESI): 341 [M+H] + .
[0190] Example 1: Preparation of Compound S-1
[0191] Step 1: Dissolve intermediate 2 (300 mg, 829.63 μmol) and ethynyl(triisopropyl)silane (151.31 mg, 829.63 μmol) in N,N-dimethylformamide (10 mL). Under argon, add cuprous iodide (31.60 mg, 165.93 μmol), bistriphenylphosphine palladium dichloride (116.46 mg, 165.93 μmol), and triethylamine (418.97 mg, 4.15 mmol) sequentially. Heat to 100°C and stir for 30 minutes. LC-MS analysis confirmed the completion of the reaction and the formation of the desired product. The reaction mixture was poured into water, extracted with dichloromethane (30 mL x 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified on a silica gel column (EA:PE = 0-50%) to afford compound S-1-a (280 mg, 672.96 μmol, 81.12% yield) as an off-white solid. MS(ESI):416.2[M+H] + .
[0192] Step 2: Dissolve compound S-1-a (230 mg, 552.79 μmol) and pinacol diboron (280.75 mg, 1.11 mmol) in 1,4-dioxane (10 mL). Under argon protection, add tris(dibenzylideneacetone)dipalladium (50.62 mg, 55.28 μmol), 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl (52.70 mg, 110.56 μmol), and potassium acetate (108.50 mg, 1.11 mmol) in sequence. Heat the mixture to 120 degrees in a microwave and stir for 30 minutes. LC-MS analysis revealed the target product. The reaction solution was poured into water, extracted with ethyl acetate (30 ml * 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column separation (EA:PE = 0-50%) to obtain yellow solid compound S-1-b (180 mg, 354.62 μmol, yield 64.15%). MS (ESI): 508.2 [M+H] + .
[0193] Step 3: Dissolve compound S-1-b (400 mg, 788.04 μmol) and intermediate 1 (240.85 mg, 1.02 mmol) in a mixture of 1,4-dioxane (10 mL) and water (1 mL). Under argon, add potassium carbonate (108.91 mg, 788.04 μmol) and bis(2-diphenylphosphinocyclopentane-2,4-dien-1-yl)iron dichloropalladium (115.32 mg, 157.61 μmol). Heat to 80°C and stir overnight. LC-MS analysis reveals the desired product. The reaction solution was poured into water, extracted with dichloromethane (30 ml x 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (EA:PE = 0-50%) to give a yellow solid compound S-1-c (300 mg, 559.90 μmol, yield 71.05%). MS (ESI): 536.1 [M+H] + .
[0194] Step 4: Dissolve compound S-1-c (10 mg, 18.66 μmol) in methanol (5 mL), add ammonium fluoride (13.81 mg, 373.26 μmol) dissolved in water (0.5 mL), and heat to 75°C under argon and stir overnight. LC-MS confirmed the reaction was complete. The reaction solution was poured into water, extracted with DCM (30 ml x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by HPLC afforded compound S-1 (1.65 mg, 4.35 μmol, yield 23.3%, 100%). MS (ESI): 380 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δ7.68(s,1H),7.53(s,1H),4.53(s,2H),4.47(s,1H),3.60–3.48(m,1H),2.37(s,3H), 2.13(s,3H),1.26(d,J=6.8Hz,3H),1.15–1.04(m,1H),0.62–0.51(m,1H),0.45–0.29(m,2H),0.25–0.16(m,1H).
[0195] Example 2: Preparation of Compound S-2
[0196] Compound S-1 and (trimethyl)silane (136.62 mg, 1.19 mmol) were dissolved in a mixture of tetrahydrofuran (5 mL) and tert-butanol (5 mL). Under argon, aqueous copper sulfate (29.61 mg copper sulfate pentahydrate dissolved in 3 mL water) and aqueous sodium ascorbate (23.49 mg sodium ascorbate dissolved in 3 mL water) were added. The mixture was then heated to 70°C and stirred overnight. LC-MS analysis revealed the desired product. The reaction mixture was poured into 2.0 M hydrochloric acid and stirred for 2 hours. The mixture was extracted with dichloromethane (30 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Compound S-2 was isolated and purified by HPLC to yield compound S-2 (2.39 mg, 5.56 μmol, 4.69% yield, 98.34% purity). MS (ESI): 423 [M+H]. + . 1 H-NMR(400MHz,DMSO-d6)δ12.26(s,1H),8.84(s,1H),8.14(s,1H),7.67(s,1H),4.62(s,2H),3.71–3.53(m,1H),2.42( s,3H),2.14(s,3H),1.28(d,J=6.8Hz,3H),1.17–1.07(m,1H),0.63–0.52(m,1H),0.46–0.32(m,2H),0.28–0.18(m,1H).
[0197] Example 3: Preparation of Compound S-3
[0198] Step 1: Dissolve intermediate 7 (640 mg, 2.17 mmol) in pyridine (15 mL), then add dimethylsulfamoyl chloride (8 g, 55.71 mmol). Stir the reaction at 80°C for 2 hours. Add water, extract with DCM, dry over anhydrous sodium sulfate, and spin-dry the solvent. The resulting crude product is separated by combiflash (0-30% EA / PE) to afford the white solid product S-3-a (176 mg, 20.18% yield). MS (ESI): 402.1 [M+H] + .
[0199] Step 2: Dissolve N-(4-methylthiazol-2-yl)acetamide (46.59 mg, 298.28 μmol), cesium carbonate (194.37 mg, 596.56 μmol), palladium acetate (13.39 mg, 59.66 μmol), and tri-tert-butylphosphine tetrafluoroborate (17.31 mg, 59.66 μmol) in DMF (5 mL). After nitrogen purge, a solution of compound S-3-a (80 mg, 198.85 μmol) in DMF (1 mL) was added dropwise at 100°C. The mixture was stirred at 100°C for 2 hours. The solvent was evaporated to dryness and the crude product was purified by combiflash (MeOH:DCM = 0-10%). The crude product was then purified by an alkaline method to afford compound S-3 (15.45 mg, 16.27% yield). MS (ESI): 478.2 [M+H] + . 1 H-NMR (400MHz, DMSO-d6) δ12.22(s,1H), 9.63(s,1H), 7.41(s,1H), 7.35(s,1H), 4.62(s,2H), 3.56-3.52(m,1H), 2.80(s, 6H),2.40(s,3H),2.16(s,3H),1.31(m,3H),1.17-1.14(m,1H),0.58-0.56(m,1H),0.43-0.37(m,2H),0.26-0.24(m,1H).
[0200] Example 4: Preparation of Compound S-4
[0201] Step 1: Dissolve intermediate 3 (500 mg, 1.27 mmol) and sodium hydroxide (151.80 mg, 3.80 mmol) in tetrahydrofuran (20 mL), cool to 0°C, and then add hydrogen peroxide (430.32 mg, 3.80 mmol, 30% purity). The reaction is stirred at room temperature for 2 hours. Water is added to the reaction solution, and the mixture is extracted with EA. The organic phase is washed with sodium sulfite solution, dried, and the solvent is evaporated. The resulting crude product is separated by a Combiflash column (0-70% EA / PE) to afford intermediate 17 (360 mg, 99.75% yield). MS (ESI): 286.1 [M+H] + .
[0202] Step 2: Intermediate 17 (360 mg, 1.26 mmol) and pyridine (311.12 mg, 3.93 mmol) were dissolved in dichloromethane (10 mL), and trifluoromethanesulfonic anhydride (721.32 mg, 2.56 mmol) was added. The reaction was stirred at 0°C for 0.5 hours. Water was added to the reaction solution, extracted with DCM, dried over anhydrous sodium sulfate, and dried under reduced pressure. The crude product was separated by Combiflash column (0-80% EA / PE) to afford Intermediate 18 (380 mg, 46.30% yield) as a yellow solid. MS (ESI): 418.1 [M+H] + .
[0203] Step 3: Intermediate 18 (200 mg, 0.48 mmol) and tert-butyl N-(4-methyl-5-tributyltinylthiazol-2-yl)carbamate (Intermediate 14, 361.83 mg, 0.72 mmol) were dissolved in dioxane (10 mL), and tetrakis(triphenylphosphine palladium) (55.35 mg, 0.048 mmol) was added. The reaction was stirred at 150°C for 0.5 h. The solvent was evaporated under reduced pressure, and the crude product was separated by Combiflash column (0-100% EA / PE) to afford compound S-4-a (160 mg, 87.53% yield) as a yellow solid. MS (ESI): 382.1 [M+H] + .
[0204] Step 4: Compound S-4-a (160 mg, 0.42 mmol) and triethylamine (254.69 mg, 2.52 mmol) were dissolved in dichloromethane (10 mL), cooled to 0°C, and then acetyl chloride (131.72 mg, 1.68 mmol) was added. The reaction was stirred at 0°C for 2 hours. Water was added to the reaction solution, extracted with DCM, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting crude product was purified by liquid chromatography (HPLC, preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 0%-60% acetonitrile) to obtain compound S-4 (11.10 mg, yield 6.22%). MS (ESI): 424.1 [M+H] + . 1H-NMR (400MHz, DMSO-d6) δ12.21(s,1H), 7.99(s,1H), 7.77(s,1H), 4.66(s,2H), 3.62-3.58(m,1H), 2 .42(s,3H),2.17(s,3H),1.30-1.14(m,4H),0.60-0.57(m,1H),0.44-0.37(m,2H),0.28-0.24(m,1H).
[0205] Example 5: Preparation of Compound S-5
[0206] Step 1: Dissolve 5,6,7,8-tetrahydro-1,7-naphthyridine (250 mg, 1.86 mmol) and Et3N (942 mg, 9.32 mmol) in DMF (5 mL), then add Intermediate 5 (505 mg, 1.86 mmol). The reaction mixture is heated to 65°C and stirred for 18 hours. After the reaction is complete, the reaction mixture is concentrated, water is added, and the mixture is extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated. The crude product is separated by combiflash (0-30%, ethyl acetate / petroleum ether) to obtain compound S-5-a (340 mg, 49%) as a light red solid. MS (ESI): 369.0 [M+H] + .
[0207] Step 2: Dissolve N-(4-methylthiazol-2-yl)acetamide (264 mg, 1.69 mmol), Cs2CO3 (688 mg, 2.11 mmol), diacetoxypalladium (76 mg, 338 μmol), and (t-Bu)3PHBF4 (86 mg, 295 μmol) in DMF (10 mL). Heat to 100°C under nitrogen, then add compound S-5-a (311 mg, 844.20 μmol) in DMF (10 mL) dropwise. Stir the reaction at 100°C for 1.5 hours. Concentrate to remove the solvent, dissolve and dilute with dichloromethane, filter to remove insoluble material, and concentrate again. The crude product is then purified by alkaline treatment to yield compound S-5 (84 mg, 20%). 1H-NMR (400MHz, DMSO-d6) δ12.14(1H,s),8.35(1H,d,J=3.3),7.58(1H,d,J=7.7),7.24(1H ,s),7.18(1H,dd,J=7.5,4.8),4.83(2H,s),4.52(2H,s),3.99(2H,t,J=8.9),3.61–3.50(1 H,m),3.03(2H,d,J=3.5),2.58(3H,s),2.14(3H,s),1.23(3H,d,J=6.8),1.13–1.02(1H,m) ,0.53(1H,d,J=5.5),0.36(2H,dd,J=13.3,6.6),0.22(1H,d,J=5.3).MS(ESI):489.2[M+H] + .
[0208] The following example compounds were synthesized with reference to the preparation method of compound S-5.
[0209] Example 14: Preparation of Compound S-14
[0210] Step 1: Intermediate 2 (300 mg, 829.63 μmol) and 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride (173.22 mg, 1.08 mmol) were dissolved in dioxane (6 mL). Tris(dibenzylideneacetone)dipalladium (37.99 mg, 41.48 μmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (48.00 mg, 82.96 μmol), and cesium carbonate (810.93 mg, 2.49 mmol) were added. The reaction was stirred in a microwave oven at 150°C for 0.5 h. The solvent was evaporated to dryness under reduced pressure, and the crude product was separated by Combiflash column chromatography (0-15% MeOH / DCM) to afford compound S-14-a (45 mg, 15.16% yield) as a yellow solid. MS(ESI):402.1[M+H] + .
[0211] Step 2: Dissolve N-(4-methylthiazol-2-yl)acetamide (58.93 mg, 377.27 μmol), cesium carbonate (163.89 mg, 503.02 μmol), palladium acetate (16.94 mg, 75.45 μmol), and tri-tert-butylphosphine tetrafluoroborate (21.89 mg, 75.45 μmol) in DMF (6 mL). After nitrogen purge, a solution of compound S-14-a (90 mg, 251.51 μmol) in DMF (2 mL) was added dropwise at 100°C. The mixture was stirred at 100°C for 2 hours. The solvent was dried by rotary evaporation and purified by combiflash (MeOH:DCM = 0-10%) to obtain the crude product. The crude product was then subjected to an alkaline method to afford compound S-14 (8.39 mg, 6.58% yield). MS (ESI): 478.2 [M+H] + . 1 H-NMR (400MHz, DMSO-d6) δ12.16(s,1H), 8.51(s,1H), 7.26(s,1H), 7.01(s,1H), 4.62(s,2H), 4.53(s,2H), 4.29-4.26(m,2H), 3.73-3.70(m,2H) ), 3.59-3.55(m,1H), 2.41(s,3H), 2.16(s,3H),1.27-1.25(m,3H), 1.12 -1.07(m,1H),0.57-0.55(m,1H),0.41-0.36(m,2H),0.23-0.20(m,1H).
[0212] Example 15: Preparation of Compound S-15
[0213] Prepared by the method of reference compound S-14. 1 H-NMR (400MHz, DMSO-d6) δ12.16(s,1H), 7.99(s,1H), 7.26(s,1H), 7.01(s,1H), 4.61(s,2H), 4.53(s,2H), 4.29-4.26(m,2H), 3.85-3.82(m,2H) ), 3.60-3.55(m,1H), 2.41(s,3H), 2.16(s,3H),1.28-1.26(m,3H), 1.12 -1.09(m,1H),0.57-0.55(m,1H),0.39-0.36(m,2H),0.23-0.20(m,1H).
[0214] Example 19: Preparation of Compound 19
[0215] Step 1: Dissolve intermediate 2 (500 mg, 1.4 mmol) in DMF (15 mL), add tributyl(1-ethoxyethylene)tin (600 mg, 1.66 mmol), bistriphenylphosphine palladium dichloride (100 mg, 0.14 mmol), and triethylamine (353 mg, 3.5 mmol). Replace the mixture with argon three times, and heat the oil bath to 100°C for 16 hours. After cooling, the reaction mixture was diluted with water (30 mL) and filtered. The filter cake was rinsed with a small amount of ethyl acetate and extracted with ethyl acetate (50 mL x 3). The organic phase was separated and dried over anhydrous sodium sulfate, filtered, and dried to give compound S-19-a (430 mg, brown oil). The product was used directly in the next reaction. MS (ESI): 306.1 [M+H] + .
[0216] Step 2: Dissolve compound S-19-a (150 mg, 0.49 mmol) in acetone (15 mL), add hydrochloric acid (0.5 mL, 2 mol / L), and stir at 0°C under argon for 1 hour. LCMS monitoring indicates product formation. Pour the reaction mixture into 100 mL of saturated sodium bicarbonate aqueous solution and extract with dichloromethane (30 mL x 3). Separate the layers, dry the organic phase over anhydrous sodium sulfate, filter, concentrate under reduced pressure, and purify on a normal phase column to obtain compound S-19-b (110 mg) in an 81% yield. 1 H-NMR (400MHz, DMSO-d6) δ7.83(d,J=1.7Hz,1H),7.46(d,J=1.8Hz,1H),4.60(s,2H),3.55(dd,J=9 .2,6.9Hz,1H),2.63(d,J=2.9Hz,3H),1.28(d,J=6.8Hz,3H),1.15–1.06(m,1H),0.59–0.21(m,4H).
[0217] Step 3: Dissolve compound S-19-b (100 mg, 0.36 mmol) in tetrahydrofuran (3 ml) and, under argon protection and in an ice bath, add methylmagnesium bromide (0.36 ml, 1.08 mol, 3 mol / L) dropwise. Stir and react for 1 hour. LCMS monitoring indicates product formation. Pour the reaction solution into 30 ml of ice-water mixture, adjust the pH to 6 with acetic acid, extract with dichloromethane (30 ml x 3), separate the layers, and dry the organic phase over anhydrous sodium sulfate, filter, and concentrate under reduced pressure to obtain compound S-19-c (88 mg). MS (ESI): 294.3 [M+H] + .
[0218] Step 4: Compound S-19-c (2.6 g, 8.8 mmol) was dissolved in DMF (35 mL), and N-(4-methylthiazol-2-yl)acetamide (2.08 mg, 13.3 mmol), tri-tert-butylphosphine tetrafluoroborate (1.02 g, 3.52 mmol), cesium carbonate (5.72 g, 17.6 mmol), and palladium acetate (394 mg, 1.76 mmol) were added. The argon atmosphere was strictly replaced three times, and the oil bath was heated to 100°C for 3 hours. After cooling, the reaction solution was diluted with water (30 ml), filtered, and the filter cake was rinsed with a small amount of ethyl acetate. The filter cake was extracted with ethyl acetate (50 mL x 3), separated, and the organic phase was dried over anhydrous sodium sulfate, filtered, and the crude product was dissolved in a small amount of dimethylformamide and prepared (preparative column: Welch Xtimate C 18 The product was separated and purified by lyophilization with 10 mM NH₄.HCO₃ aqueous solution / acetonitrile (elution phase: 10 mM NH₄.HCO₃ aqueous solution / acetonitrile, elution gradient: start 45% acetonitrile - end 50% acetonitrile, flow rate: 30 mL / min), and then lyophilized to obtain compound S-19 (1.1 g) in a yield of 30.3%. MS (ESI): 414.2 [M+H] + ; 1 H-NMR (400MHz, DMSO-d6) δ12.19(s,1H),7.59(d,J=1.1Hz,1H),7.45(d,J=1.2Hz,1H),7.17(s,1H),4.66(s,2H),3.64(dd,J=9.2,6.8Hz,1H),2.51–2. 49(m,3H),2.16(s,3H),1.56(s,6H),1.31(d,J=6.8Hz,3H),1.16(dd,J=10. 9, 6.6Hz, 1H), 0.72–0.53 (m, 1H), 0.48–0.33 (m, 2H), 0.26 (d, J = 5.5Hz, 1H).
[0219] Example 20: Preparation of Compound S-20
[0220] Step 1: Dissolve intermediate 2 (350 mg, 967.91 μmol) in THF (5 mL). Add isopropylmagnesium bromide (2.8 M, 1.04 mL) under ice (0°C). The mixture is stirred at 0°C for 0.5 hours. 3-Oxetanone (209.25 mg, 2.90 mmol) is then added at 0°C. The mixture is stirred at room temperature for 1 hour until the reaction is complete. The reaction mixture is cooled to room temperature and concentrated to dryness under reduced pressure. The dried product is subjected to combiflash (MeOH:DCM = 0-10%) to obtain an oil. TLC (EA:PE = 1:4) yields compound S-17-a (202 mg, 67.81%) as a white solid. MS (ESI): 308.1 [M+H] + .
[0221] Step 2: Dissolve N-(4-methylthiazol-2-yl)acetamide (76.13 mg, 487.37 μmol), cesium carbonate (317.59 mg, 974.75 μmol), palladium acetate (21.88 mg, 97.47 μmol), and tri-tert-butylphosphine tetrafluoroborate (28.28 mg, 97.47 μmol) in DMF (3 mL). After nitrogen purge, a solution of compound S-17-a in DMF (1 mL) was added dropwise at 100°C. The mixture was stirred and reacted at 100°C for 3 hours until the reaction was complete. The reaction mixture was filtered, and the filtrate was concentrated to dryness under reduced pressure. The dried product was purified by combiflash (MeOH:DCM = 0-20%) to obtain the crude product, which was then subjected to an alkaline method to yield compound S-17 (58.48 mg, 41.72%). MS (ESI): 285.1 [M+H] + . Purity: 99.09%. 1H-NMR(400MHz,DMSO-d6)δ12.20(s,1H),7.67(s,1H),7.55(s,1H),7.02 (s,1H),4.97–4.85(m,2H),4.74(d,J=7.0Hz,2H),4.66(s,2H),3.63–3.5 5(m,1H),2.42(s,3H),2.16(s,3H),1.29(d,J=6.8Hz,3H),1.14(d,J=8.2 Hz,1H),0.58(s,1H),0.41(dd,J=13.5,6.4Hz,2H),0.24(d,J=5.3Hz,1H).
[0222] Step 3: Compound S-17 (15 mg, 35.09 μmol) was dissolved in DCM (5 mL), cooled to -10°C, and DAST (16.97 mg, 105.26 μmol) was slowly added dropwise. The mixed solution was naturally warmed to room temperature (22°C) and stirred for 3 hours until the reaction was complete. The reaction solution was concentrated under reduced pressure to dryness to obtain a crude product. The crude product was then subjected to an alkaline method to obtain compound S-20 (5.93 mg, 39.35%). MS (ESI): 430.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δ12.19(s,1H),7.57(s,1H),7.50(dd,J=4.7,1.5Hz, 1H),7.15(dd,J=7.9,1.5Hz,1H),6.77(dd,J=7.9,4.8Hz,1H),4.58(s,2H),4. 38(s,2H),4.02(s,2H),3.44–3.38(m,1H),2.59(s,3H),2.15(s,3H),1.22(d, J=6.8Hz,3H),1.06(s,1H),0.54(s,1H),0.34(d,J=32.7Hz,2H),0.16(s,1H).
[0223] Example 22: Preparation of Compound S-22
[0224] Step 1: Intermediate 2 (300 mg, 0.83 mmol) and cuprous cyanide (300 mg, 3.35 mmol) were dissolved in DMSO (5 mL) and reacted at 100°C in a microwave oven for 5 hours. LCMS and TLC monitoring revealed that after the reaction was complete, water was added and the mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was purified by combiflash (0-50%, ethyl acetate / petroleum ether) to afford Intermediate 19 (150 mg, 70%) as a pale yellow solid. MS (ESI): 261.0 [M+H] + .
[0225] Step 2: Dissolve N-(4-methylthiazol-2-yl)acetamide (60 mg, 0.38 mmol), Cs2CO3 (124 mg, 0.38 mmol), diacetoxypalladium (10 mg, 44 μmol), and (t-Bu)3PHBF4 (15 mg, 51 μmol) in DMF (5 mL). Heat to 100°C under nitrogen. Then, slowly add a solution of Intermediate 10 (50 mg, 0.19 mmol) in DMF (5 mL) dropwise over approximately 1 hour. The reaction is stirred at 100°C for 1.5 hours. After completion of the reaction, water is added and the mixture is extracted with ethyl acetate. The organic phase is dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated. The crude product is purified by combiflash (20-85% ethyl acetate / petroleum ether) to afford compound S-22 (5.58 mg, 38%). MS (ESI): 381.0 [M+H]. + . 1 H-NMR (400MHz, DMSO-d6) δ12.27(s,1H),7.99(d,J=0.9Hz,2H),4.63(s,2H),3.57(dd,J=9.3,6.8Hz,1H),2.39(s,3H),2.15(s,3H),1 .29(d,J=6.8Hz,3H),1.16–1.05(m,1H),0.57(ddd,J=10.6,5.5,3.4Hz,1H),0.39(ddd,J=9.6,6.6,3.7Hz,2H),0.24(q,J=5.3Hz,1H).
[0226] The following examples were synthesized with reference to the preparation method of compound S-5 or S-14.
[0227] Example 26: Preparation of Compound S-26
[0228] Step 1: Intermediate 5 (271 mg, 1.0 mmol) and 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (123 mg, 1.0 mmol) were dissolved in DMF (5 mL), and 1 ml of triethylamine was added. The mixture was heated at 90°C for 16 hours. After the reaction was complete, the reaction solution was concentrated, water was added, and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was separated and purified by combiflash (15-100%, ethyl acetate / petroleum ether) to obtain compound S-26-a (200 mg, 56%) as a light yellow solid. MS (ESI): 358.0 [M+H] + .
[0229] Step 2: Compound S-26-a (200 mg, 0.56 mmol), sodium carbonate (118 mg, 1.12 mmol), Pd(dppf)Cl2 (25 mg, 34.2 μmol), and intermediate 6 (316 mg, 1.12 mmol) were dissolved in 1,4-dioxane (5 mL), and 0.5 ml of water was added. The mixture was heated to 100°C under nitrogen and stirred for 1.5 hours. After the reaction, water was added and the mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was separated and purified by combiflash (20-100%, ethyl acetate / petroleum ether) to obtain the product compound S-26 (50 mg, 18.7%). MS (ESI): 478.0 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δ12.21–12.09(m,1H),7.45(s,1H),7.21(s,1H), 4.62(s,2H),4.50(s,2H),3.92(d,J=6.2Hz,2H),3.61–3.49(m,1H),2.90(d ,J=5.6Hz,2H),2.57(s,3H),2.14(s,3H),1.23(d,J=6.8Hz,4H),0.55(dt,J =8.6,5.3Hz,1H),0.36(td,J=10.3,9.8,6.3Hz,2H),0.21(q,J=4.7Hz,1H).
[0230] Example 27: Preparation of Compound S-27
[0231] Step 1: Intermediate 5 (600 mg, 2.21 mmol), 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine (545.05 mg, 4.43 mmol), and DIPEA (286.00 mg, 2.21 mmol, 385.44 μL) were dissolved in dioxane (8 mL). After nitrogen purge, the mixture was stirred at 185°C in a microreactor for 0.75 h. The starting materials were essentially reacted. The reaction solution was concentrated to dryness under reduced pressure to obtain a crude product. The crude product was isolated and purified by combiflash (MeOH:DCM = 0-10%) to afford compound S-27-a (453 mg, 1.27 mmol, 57.21% yield) as a yellow oil. MS (ESI): 358.1 [M+H] + .
[0232] Step 2: Compound S-27-a (70 mg, 195.62 μmol), intermediate 6 (60.72 mg, 215.18 μmol), sodium carbonate (103.67 mg, 978.10 μmol), and PdCl2(dppf) (21.29 mg, 29.34 μmol) were dissolved in dioxane (10 mL) and water (1 mL). The mixture was purged with nitrogen and stirred in a microwave reactor at 100°C for 0.5 hours. The reaction was complete. The reaction solution was concentrated to dryness under reduced pressure and combiflashed (MeOH:DCM = 0-15%) to obtain a crude yellow solid. The crude product was purified by column chromatography to yield compound S-27 (3.26 mg, 3.29%). MS (ESI): 478.2 [M+H] + .1H-NMR(400MHz,DMSO-d6)δ12.15(s,1H),12.11–11.74(m,1H),7.49(s,1H) ),7.21(s,1H),4.57(s,2H),4.50(s,2H),3.93(dd,J=14.1,5.7Hz,2H),3.5 5(s,1H),2.82(s,2H),2.57(s,3H),2.14(s,3H),1.23(d,J=6.8Hz,3H),1.0 8(s,1H),0.54(s,1H),0.36(dd,J=13.1,6.5Hz,2H),0.21(d,J=5.4Hz,1H).
[0233] Example 28: Preparation of Compound S-28
[0234] Compound S-28 can be synthesized by referring to the method of compound S-5. MS (ESI): 475.2 [MH] - . 1 H-NMR (400MHz, DMSO-d6) δ12.14(s,1H),8.63(s,1H),8.47(d,J=4.7Hz,1H),7.47(d,J=4.9Hz,1H),7.15(s,1H),5.19(q,J=16.6Hz,4H),4.52(s,2H ),3.62–3.51(m,1H),2.59(s,3H),2.13(s,3H),1.24(d,J=6.8Hz,3H),1. 13–1.03(m,1H),0.61–0.51(m,1H),0.45–0.30(m,2H),0.28–0.19(m,1H).
[0235] Example 29: Preparation of Compound S-29
[0236] Step 1: Dissolve intermediate 5 (300 mg, 1.11 mmol), 7,7-difluoro-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-amine (275 mg, 1.44 mmol), and DIPEA (1.43 g, 11.06 mmol, 1.5 mL) in 1,4-dioxane (3.5 mL) and stir in a microwave at 180°C for 0.5 h. After complete reaction, the reaction mixture was diluted with dichloromethane and filtered to remove insoluble material. The filtrate was concentrated and separated by combiflash (0-80% EA / PE). Compound S-29-a (190 mg, 40%) was obtained as a white solid. MS (ESI): 426.1 [M+H] + .
[0237] Step 2: Compound S-29-a (100 mg, 234.81 μmol) and intermediate 6 (66 mg, 234.81 μmol) were dissolved in water (0.5 mL) and 1,4-dioxane (2 mL), and sodium carbonate (99 mg, 939.23 μmol) and Pd(dppf)Cl2 (34.36 mg, 46.96 μmol) were added. The reaction was stirred in a microwave at 100°C for 0.5 hours. After the reaction was complete, the starting materials were cooled to room temperature, diluted with dichloromethane, filtered, and the filtrate was concentrated under reduced pressure. Combiflash separation (4 g, 0-10% MeOH / DCM) and subsequent alkaline preparation successfully provided the product, compound S-29 (2.97 mg, 2.30%). 1 H-NMR (400MHz, DMSO-d6) δ12.17(s,1H),7.31(s,1H),7.17(s,2H),4.90(dd,J=31 .6,16.0Hz,2H),4.70(td,J=26.2,14.4Hz,2H),4.55(s,2H),3.56(dq,J=14.0,7.0 Hz,1H),2.55(s,3H),2.14(s,3H),1.24(d,J=6.8Hz,3H),1.07(dt,J=12.2,6.1Hz, 1H),0.58–0.50(m,1H),0.43–0.32(m,2H),0.26–0.16(m,1H).MS(ESI):546.2[MH] - .
[0238] Example 30: Preparation of Compound S-30
[0239] Step 1: Intermediate 5 (150 mg, 553.22 μmol), 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine (132.45 mg, 829.82 μmol, HCl), and DIPEA (742.00 mg, 5.74 mmol, 1 mL) were dissolved in dioxane (4 mL). The mixture was purged with nitrogen and stirred in a microreactor at 100°C for 0.75 h, resulting in complete reaction. The reaction mixture was concentrated to dryness under reduced pressure to obtain the crude product. The crude product was combiflashed (MeOH:DCM = 0-10%) to afford compound S-30-a (180 mg, 90.93%) as a yellow oil. MS (ESI): 358.1 [M+H] + .
[0240] Step 2: Compound S-30-a (60 mg, 167.67 μmol), intermediate 6 (50 mg, 177.20 μmol), PdCl2(dppf) (24.33 mg, 33.53 μmol), and sodium carbonate (88.86 mg, 838.37 μmol) were dissolved in dioxane (5 mL) and water (0.5 mL). The mixture was purged with nitrogen and stirred in a microwave reactor at 100°C for 0.75 h. The reaction was complete. The reaction solution was concentrated to dryness under reduced pressure and the dried product was purified by combiflash (MeOH:DCM = 0-15%) to obtain a crude yellow oil. The crude product was purified by column chromatography to yield compound S-30 (5.21 mg, 6.45%). MS (ESI): 478.2 [M+H] + .1H-NMR(400MHz,DMSO-d6)δ12.50(s,1H),12.18(s,1H),7.45(s,1H),7.24(s,1H),4.73(s,2H),4.53(s,2H),3.98–3.79(m,2H),3.62–3.5 1(m,1H),2.83(s,2H),2.60(s,3H),2.16(s,3H),1.26(d,J=6.8Hz,3H),1.10(s,1H),0.56(s,1H),0.44–0.33(m,2H),0.24(d,J=5.1Hz,1H).
[0241] Example 31: Preparation of Compound S-31
[0242] Step 1: Intermediate 5 (500 mg, 1.84 mmol) and 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine (272.53 mg, 2.21 mmol) were dissolved in DMF (10 mL), and triethylamine (559.80 mg, 5.53 mmol) was added. The reaction was stirred at 80°C for 20 hours. The solvent was evaporated under reduced pressure, and the crude product was separated by Combiflash column (0-15% MeOH / DCM) to give compound S-31-a (210 mg, 31.82% yield) as a yellow solid. MS (ESI): 358.0 [M+H] +
[0243] Step 2: Compound S-31-a (100 mg, 0.28 mmol) and intermediate 6 (104.59 mg, 0.31 mol) were dissolved in dioxane (8 mL) and water (1 mL). PdCl2(dppf) (20.45 mg, 0.028 mmol) and sodium carbonate (59.24 mg, 0.56 mmol) were then added. The reaction was stirred at 100°C in a microwave oven for 45 minutes. The solvent was evaporated under reduced pressure, and the crude product was separated by Combiflash column (0-80% EA / PE) to afford a yellow solid. This solid was further purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 0%-60% acetonitrile) to afford the desired product, compound S-31 (11.76 mg, yield: 8.78%). MS(ESI):478.2[M+H] + . 1 H-NMR (400MHz, DMSO-d6) δ12.20(s,1H),7.34(s,1H),7.14-7.10(m,1H),6.91-6.89(m,1H),4.82(s,2H),4.57(s,2H),4.22-4.15(m,4H),3 .59-3.55(m,1H), 2.61(s,3H), 2.16(s,3H), 1.27-1.26(m,3H), 1.13- 1.09(m,1H), 0.57-0.55(m,1H), 0.40-0.36(m,2H), 0.26-0.22(m,1H).
[0244] Example 32: Preparation of Compound S-32
[0245] Step 1: Dissolve compound S-22 (30 mg, 0.078 mmol) in toluene (2 mL), add azidotributylstannane (270 mg, 0.87 mmol), react at 120 ° C for 24 hours, filter, and send the filter cake to obtain compound S-32 (1.51 mg, white solid, purity: 97%). 1 H-NMR(400MHz,DMSO-d6)δ12.30(s,1H),8.21(s,1H),7.95(s,1H),4.79(s,2H),3.67(s,1H),2.1 8(s,3H),1.35(d,J=6.5Hz,3H),1.23(s,3H),0.85(s,1H),0.61(s,1H),0.44(s,2H),0.30(s,1H).
[0246] Example 33: Preparation of Compound S-33
[0247] Step 1: Dissolve intermediate 2 (400 mg, 1.11 mmol) in THF (10 mL). Add isopropylmagnesium bromide (2.8 M, 987.66 μL) under ice-cooling (0°C). The mixture is stirred at room temperature (22°C) for 1 hour. Dicyclopropyl ketone (609.25 mg, 5.53 mmol) is then added under ice-cooling (0°C). The mixture is stirred at room temperature (22°C) for 1 hour. The reaction is complete. The reaction mixture is concentrated to dryness under reduced pressure and combiflashed (MeOH:DCM = 0-15%) to obtain the crude product. The crude product is purified by TLC (EA:PE = 1:4) to obtain compound S-33-a (125 mg, 32.67%) as a white solid. MS (ESI): 328.2 [M+H] + .
[0248] Step 2: Dissolve 2-acetamido-4-methylthiazole (108.39 mg, 693.92 μmol), cesium carbonate (282.61 mg, 867.40 μmol), palladium acetate (23.37 mg, 104.09 μmol), and tri-tert-butylphosphine tetrafluoroborate (30.20 mg, 104.09 μmol) in DMF (3 mL). After nitrogen purge, a solution of compound S-33-a (120 mg, 346.96 μmol) in DMF (2 mL) was slowly added dropwise at 100°C. The mixture was stirred at 100°C for 3 hours. The reaction was complete. The reaction mixture was concentrated under reduced pressure to dryness to obtain a crude product, which was then combiflashed (EA:PE = 40-80%) to afford compound S-51 (122 mg, 75.52%) as a pale yellow solid. MS (ESI): 448.2 [M+H] + .
[0249] Step 3: Compound S-51 (90 mg, 193.30 μmol) was dissolved in DCM (10 mL) and DAST (155.79 mg, 966.48 μmol) was added dropwise at -20°C. The mixed solution was naturally warmed to room temperature (22°C) and stirred for 18 hours. The reaction was complete. The reaction solution was concentrated to dryness under reduced pressure, and the dried product was subjected to combiflash (EA:PE = 0-80%) to obtain a crude product. The crude product was purified by column chromatography to obtain the product compound S-33 (3.40 mg, 3.76%). MS (ESI): 468.3 [M+H] + .1H-NMR(400MHz,DMSO-d6)δ12.20(s,1H),7.57(s,1H),7.00(s,1H),5.40(t,J=7.1Hz,1H) ,4.61(t,J=6.5Hz,1H),4.53(s,2H),4.49(t,J=6.5Hz,1H),3.60–3.52(m,1H),2.80–2.67( m,2H),2.38(s,3H),2.15(s,3H),2.06(s,1H),1.26(d,J=6.8Hz,3H),1.09(s,1H),0.63(d, J=8.4Hz,2H),0.56(s,1H),0.43–0.32(m,2H),0.22(d,J=5.1Hz,1H),0.11(d,J=3.9Hz,2H).
[0250] Example 34: Preparation of Compound S-34
[0251] Step 1: Dissolve compound S-38 (30 mg, 0.079 mmol) and tributylstannane (261 mg, 0.79 mmol) in toluene (2 mL). Replace the argon atmosphere three times and react in an oil bath at 120°C for 36 hours. Cool the reaction mixture to room temperature, filter, and wash the filter cake twice with dichloromethane. Dissolve the filter cake in dimethyl sulfoxide (5 mL) and purify with an alkaline preparative to afford compound S-34 (1.21 mg, white solid, 99% purity). 1H-NMR (400MHz, DMSO-d6) δ12.29(s,1H),8.10(s,1H),5.33(t,J=4.9Hz,1H),4.82(s,2H),3.68–3.53(m,1H),2.69(s,3H),2. 19 (s, 3H), 1.33 (d, J = 6.8Hz, 3H), 0.86 (t, J = 6.7Hz, 1H), 0.61 (t, J = 6.8Hz, 1H), 0.44 (d, J = 5.4Hz, 2H), 0.28 (d, J = 5.5Hz, 1H).
[0252] Example 35: Preparation of Compound S-35
[0253] Step 1: Dissolve intermediate 2 (800 mg, 2.16 mmol) in anhydrous methanol (50 mL), add TEA (800 mg, 7.92 mmol) and Pd(PPh3)2Cl2 (160 mg, 0.16 mmol), and introduce carbon monoxide into the mixture. Autoclave the mixture at 4 MPa and 80°C for 16 hours. LCMS analysis indicated the reaction was complete. The reaction mixture was transferred to 100 mL of water and extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with saturated sodium chloride solution (100 mL x 1), dried over anhydrous sodium sulfate, and purified by normal phase column chromatography to obtain compound S-35-a (500 mg) in a yield of 76.94%. MS (ESI): 294.0 [M+H] + . 1 H-NMR (400MHz, DMSO-d6) δ7.64(d,J=1.7Hz,1H),7.44(d,J=1.8Hz,1H),4.36(s,2H),3.61(s,3 H), 3.30 (dd, J=9.2, 6.9Hz, 1H), 1.04 (d, J=6.8Hz, 3H), 0.92–0.84 (m, 1H), 0.38–-0.04 (m, 4H).
[0254] Step 2: Compound S-35-a (450 mg, 1.53 mmol) was dissolved in 1,4-dioxane (20 mL) and water (4 mL). Intermediate 6 (1.729 g, 6.13 mmol) and sodium carbonate (487 mg, 4.60 mmol) were added and the atmosphere was purged with argon. Pd(dppf)Cl2 (168 mg, 0.23 mmol) was then added and the atmosphere was purged with argon. The mixture was stirred at 100°C for 3 hours under argon protection. LCMS confirmed the reaction was complete. The reaction solution was transferred to water and extracted with ethyl acetate (100 mL × 3). The combined organic phases were washed with saturated sodium chloride aqueous solution (100 mL × 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by normal phase column chromatography afforded compound S-35-b (277 mg) in a yield of 40.77%. MS (ESI): 414.1 [M+H ]+ . 1 H-NMR (400MHz, DMSO-d6) δ12.23(s,1H),7.81(s,1H),7.59(d,J=1.5Hz,1H),4.62(s,2H),3.84(s,3H),3.62–3.48(m,1H) ,2.40(s,3H),2.16(s,3H),1.28(d,J=6.8Hz,3H),1.12(dd,J=8.8,3.6Hz,1H),0.40(dddd,J=54.9,17.9,8.8,4.0Hz,4H).
[0255] Step 3: Dissolve compound S-35-b (277 mg) in 15 mL of tetrahydrofuran, replace with argon, and add 1 M lithium hydroxide aqueous solution (2.5 mL). Stir and react at room temperature for 1 hour. LCMS analysis indicates the reaction is complete. The reaction solution is dried and purified on a reverse phase column to obtain compound S-35-c (268 mg) in a yield of 98.22%. MS (ESI): 400.0 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δ7.63(s,1H),7.56(s,1H),4.58(s,2H),3.61–3.55(m,1H),2.39(s,3H),2.14(s,3H),1 .29(d,J=6.6Hz,3H),1.13(s,1H),0.63–0.55(m,1H),0.41(dd,J=12.3,5.8Hz,2H),0.26(dd,J=9.9,4.2Hz,1H).
[0256] Step 4: Compound S-35-c (220 mg, 0.55 mmol) was dissolved in DMF (10 mL), and then formic hydrazide (36 mg, 0.61 mmol), N-methylmorpholine (167 mg, 1.65 mmol), and HATu (251 mg, 0.66 mmol) were added. The atmosphere was replaced with argon, and the mixture was stirred at room temperature for 16 hours. LCMS analysis showed that the reaction was complete. The reaction solution was transferred to water (100 mL) and extracted with dichloromethane (100 mL × 3). The combined organic phases were washed with saturated sodium chloride solution (100 mL × 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by normal phase column chromatography to obtain compound S-35-d (300 mg). MS (ESI): 442.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δ13.82(s,1H),12.26(s,1H),10.57(s,1H),8.30(d,J =1.2Hz,1H),8.09(s,1H),7.97(s,1H),4.76(s,2H),3.67(dd,J=9.1,6.9Hz,1H ),2.45(s,3H),2.17(s,3H),1.34(d,J=6.8Hz,3H),1.19(dd,J=8.2,4.4Hz,1H) ,0.62(dd,J=11.7,6.4Hz,1H),0.45(dd,J=12.7,7.0Hz,2H),0.32–0.27(m,1H).
[0257] Step 5: Compound S-35-d (270 mg, 0.61 mmol) was dissolved in DCM (20 mL), and Burgess reagent (432 mg, 1.83 mmol) was added. The mixture was replaced with argon, and the mixture was stirred at room temperature for 48 hours. LCMS confirmed the reaction was complete. The product was spin-dried and sent for preparative purification. Prep-TLC was performed to obtain compound S-35 (0.91 mg, white solid) in a yield of 0.29%. MS (ESI): 424.3 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δ12.25(s,1H),9.43(s,1H),7.97(s,1H),7.82(s,1H),4.68(s,2H),3.53(s,1H), 2.43(s,3H),2.17(s,3H),1.29(d,J=6.8Hz,3H),1.15–1.05(m,1H),0.58(s,1H),0.35(s,2H),0.22(s,1H).
[0258] Example 37: Preparation of Compound S-37
[0259] Step 1: Dissolve compound S-47-a (500 mg, 1.28 mmol) and trimethyl((tributyltin)ethynyl)silane (995 mg, 2.56 mmol) in toluene (20 ml), then add tetrakistriphenylphosphine palladium (45 mg, 0.03 mmol), protect with argon, and react in an oil bath at 120°C for 16 hours. The reaction solution was cooled to room temperature and extracted three times with ethyl acetate and water. The organic phases were combined, backwashed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound S-37-a (500 mg, crude product, yellow solid).
[0260] Step 2: Compound S-37-a (450 mg, 0.99 mmol) was dissolved in dichloromethane (9 ml) and methanol (3 mL), followed by the addition of potassium carbonate (206 mg, 1.49 mmol). The reaction mixture was allowed to react at room temperature for 2 h. The reaction mixture was filtered, the filtrate was concentrated, and then purified by column chromatography (silica, petroleum ether-ethyl acetate) to yield compound S-37 (6.09 mg, light yellow solid, 91% purity). 1 H-NMR (400MHz, DMSO-d6) δ11.87(s,1H),7.68(s,1H),4.40(s,1H),4.35(d,J=20.7Hz,2H),3.33(dq,J=13.7,6.9Hz,1H),2.43 –2.32(m,3H),1.94(s,3H),1.04(d,J=6.8Hz,3H),0.94–0.82(m,1H),0.41–0.28(m,1H),0.24–0.10(m,2H),0.06–0.06(m,1H).
[0261] Example 38: Preparation of Compound S-38
[0262] Step 1. Dissolve compound S-47-a (100 mg, 0.256 mmol) in N,N-dimethylformamide (3 ml). Add zinc cyanide (150 mg, 1.28 mmol), 1,1'-bis(diphenylphosphino)ferrocene (56.7 mg, 0.1 mmol), and activated zinc powder (16.6 mg, 0.256 mmol). Bubble argon into the reaction solution for 30 seconds. Add tris(dibenzylideneacetone)dipalladium (46.6 mg, 0.05 mmol) and continue bubbling argon into the reaction solution for one minute. Microwave at 125°C for one hour. Cool the reaction solution to room temperature, filter, and wash the filter cake twice with dichloromethane. Slurry the filter cake with dimethyl sulfoxide (5 mL) for another 30 minutes, filter, and pump dry using an oil pump to obtain compound S-38 (50 mg, gray solid) in a 51% yield. 1 H-NMR(400MHz,DMSO-d6)δ12.92–11.68(m,1H),8.20(s,1H),4.71(s,2H),3.71–3.49(m,1H),2.63(s,3H),2.1 8(s,3H),1.31(d,J=6.8Hz,3H),1.24(s,1H),0.59(t,J=7.0Hz,1H),0.48–0.35(m,2H),0.27(d,J=4.9Hz,1H).
[0263] Example 41: Preparation of Compound S-41
[0264] Step 1: Intermediate 2 (1.6 g, 4.42 mmol) was dissolved in tetrahydrofuran (30 mL) and cooled to 0°C under argon. Isopropylmagnesium bromide (3.0 M, 2.21 mL) was added dropwise over 2 minutes. Acetone (1.28 g, 22.12 mmol) was then added dropwise. The reaction mixture was allowed to react after 3 minutes. The reaction mixture was poured into water, extracted with dichloromethane (30 ml x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The mixture was purified by silica gel column chromatography (EA:PE = 0-30%) to afford compound S-41-a (750 mg, yellow solid). Yield: 57.70%. MS (ESI): 294 [M+H] + .
[0265] Step 2: Compound S-41-a (650 mg, 2.21 mmol) was dissolved in dichloromethane (10 mL) and cooled to 0°C under argon. 2-Methoxy-N-(2-methoxyethyl)-N-(trifluorosulfonyl)ethylamine (978.98 mg, 4.42 mmol) was added and stirred at 0°C for 2 hours, then at room temperature overnight. The reaction mixture was poured into water, extracted with dichloromethane (30 mL x 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (EA:PE = 0-50%) to afford compound S-41-b (35 mg, white solid) in a yield of 5.35%. MS (ESI): 298 [M+H] + .
[0266] Step 3: Compound S-41-b (30 mg, 101.43 μmol) and intermediate 6 (143.10 mg, 507.14 μmol) were dissolved in a mixture of 1,4-dioxane (3 mL) and water (0.5 mL). Pd(dppf)Cl2 (37.11 mg, 50.71 μmol) and sodium carbonate (53.75 mg, 507.14 μmol) were added under argon. The mixture was heated to 120°C and stirred for 1.5 hours. The reaction mixture was poured into water, extracted with dichloromethane (30 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The mixture was separated and purified by HPLC to obtain compound S-41 (1.50 mg, white solid, 97.11% purity) in a yield of 3.46%. MS (ESI): 416 [M+H] + .
[0267] Example 49: Preparation of Compound S-49
[0268] Step 1: Intermediate 5 (300 mg, 1.11 mmol) and 3-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (764.38 mg, 5.53 mmol) were dissolved in 1,4-dioxane (5 mL). N,N-diisopropylethylamine (714.99 mg, 5.53 mmol) was added under argon. The mixture was heated to 100°C and stirred for 1 hour. The reaction mixture was concentrated to dryness under reduced pressure and purified on a silica gel column to afford S-49-a (350 mg, yellow oil) in an 84.84% yield. MS (ESI): 373 [M+H]. + .
[0269] Step 2: Compound S-49-a (175 mg, 469.36 μmol) and intermediate 16 (479.09 mg, 1.41 mmol) were dissolved in a mixture of 1,4-dioxane (10 mL) and water (1 mL). Pd(dppf)Cl2 (103.03 mg, 140.81 μmol) and sodium carbonate (129.74 mg, 938.71 μmol) were added sequentially under argon. The mixture was heated to 100°C and stirred for 20 minutes. The reaction mixture was poured into water and extracted with dichloromethane (30 mL x 2). The organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified on a silica gel column to afford compound S-49-b (200 mg, yellow solid) in a yield of 77.38%. MS (ESI): 551 [M+H]. + .
[0270] Step 3: Dissolve compound S-49-b (250 mg, 453.99 μmol) in dichloromethane (3 mL). Add trifluoroacetic acid (16.55 mg, 145.17 μmol) with stirring at room temperature. Stir at room temperature for 1 hour. The reaction mixture is then concentrated under reduced pressure to afford compound S-49-c (150 mg, yellow solid). Yield: 73.33%. MS (ESI): 451 [M+H] + .
[0271] Step 4: Compound S-49-c (60 mg, 133.17 μmol) was dissolved in DCM (10 mL) and cooled to 0°C under argon. Diisopropylethylamine (86.06 mg, 665.84 μmol) and acetyl chloride (15.68 mg, 199.75 μmol) were added and stirred at 0°C for 1 hour. The reaction mixture was poured into water, extracted with dichloromethane (30 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by HPLC afforded compound S-49 (3.92 mg, yellow solid, 95.34% purity), yield: 5.70%. MS (ESI): 493 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δ12.20(s,1H),7.34(s,1H),4.91(s,2H),4.55(s,2H),4.22–4.02(m,4H),3.61–3.48(m,1H),2.59(s,3 H), 2.30 (s, 3H), 2.14 (s, 3H), 1.25 (d, J = 6.8Hz, 3H), 1.13–1.02 (m, 1H), 0.59–0.51 (m, 1H), 0.42–0.29 (m, 2H), 0.26–0.18 (m, 1H).
[0272] Compound S-36 can be synthesized by referring to the preparation method of compound S-2. Compound S-39 can be synthesized by referring to the preparation method of compound S-20. Compounds S-40, S-45, S-46, S-48, and S-52 can be synthesized by referring to the preparation method of compound S-5 or S-14. Compound S-42 can be synthesized by referring to the preparation method of compound S-20.
[0273] Example 47: Preparation of Compound S-47
[0274] Step 1: Intermediate 5 (1.200 g, 4.43 mmol) and intermediate 6 (3.75 g, 13.28 mmol) were dissolved in N,N-dimethylformamide (20 mL). Under argon, bis(2-diphenylphosphinocyclopentane-2,4-dien-1-yl)iron dichloropalladium (323.83 mg, 442.57 μmol) and sodium carbonate (1.41 g, 13.28 mmol) were added. The mixture was heated to 100°C and stirred for 10 hours. LC-MS analysis revealed the desired product. The reaction mixture was poured into water, extracted with dichloromethane (50 ml x 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified on a silica gel column (EA:PE = 0-100%) to afford compound S-47-a (380 mg, 972.15 μmol, yield 21.97%) as a yellow solid. MS (ESI): 391 [M+H] + .
[0275] Step 2: Compound S-47-a (380 mg, 972.15 μmol) was dissolved in 1,4-dioxane (15 mL) and cooled to -78°C under argon. Tetrakistriphenylphosphine palladium (101.99 mg, 97.21 μmol) was added dropwise. The mixture was stirred at -78°C for 2 hours. Dibutyl-(1-ethoxyvinyl)-propyltin (674.91 mg, 1.94 mmol) was added dropwise, and stirring was continued at -78°C for 2 hours. LC-MS analysis revealed the desired product. The reaction mixture was directly concentrated to dryness under reduced pressure and purified on a silica gel column (EA:PE = 0-100%) to afford compound S-47-b (230 mg, 539.23 μmol, 55.47% yield) as a yellow solid. MS (ESI): 427 [M+H] + .
[0276] Step 3: Compound S-47-b (230 mg, 539.23 μmol) was dissolved in dichloromethane (20 mL). Trifluoroacetic acid (19.66 mg, 172.43 μmol, 1 mL) was added with stirring at room temperature and stirred for 1 hour. LC-MS analysis revealed the desired product. The reaction mixture was poured into a 1:1 mixture of saturated sodium bicarbonate solution and ice, extracted with dichloromethane (100 mL x 3), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford compound S-47-c (214.87 mg, 539.23 μmol, 100.00% yield) as a red solid.
[0277] Step 4: Compound S-47-c (214 mg, 537.04 μmol) was dissolved in tetrahydrofuran (10 mL), cooled to 0°C under argon, and methylmagnesium bromide (1.0 M, 1.61 mL) was added dropwise. The mixture was stirred at 0°C for 25 minutes and then post-processed. LC-MS analysis revealed the target product. The reaction mixture was poured into water, extracted with DCM (50 ml x 3), dried over anhydrous sodium sulfate, and purified by HPLC (preparative column: Welch Xtimate C 18 Compound S-47 (51.32 mg, 123.81 μmol, yield 23.05%) was isolated and purified using a 10 mM NH₄.HCO₃ aqueous solution / acetonitrile solution, elution gradient: start 43% acetonitrile - end 48% acetonitrile, flow rate: 30 mL / min). MS (ESI): 415 [M+H] + . 1 H-NMR (400MHz, DMSO-d6) δ12.21(s,1H),7.77(s,1H),7.26(s,1H),4.72(s,2H),3.60(dq,J=14.0,7.0Hz,1H),2.59(s,3H), 2.14(s,3H),1.5(s,6H),1.29(d,J=6.8Hz,3H),1.18–1.06(m,1H),0.63–0.49(m,1H),0.47–0.31(m,2H),0.30–0.18(m,1H).
[0278] Example 53: Preparation of Compound S-53
[0279] Step 1: Dissolve intermediate 5 (500 mg, 1.84 mmol), intermediate 13 (325 mg, 1.75 mmol), and DIPEA (2.23 g, 17.22 mmol, 3.00 mL) in 1,4-dioxane (8 mL) and stir in a microwave at 130°C for 1 hour. After the reaction was complete, the reaction solution was diluted with dichloromethane and filtered to remove insoluble material. The filtrate was concentrated and separated by combiflash (0-80% EA / PE). Compound S-53-a (320 mg, 41%) was obtained as a white solid. MS (ESI): 421.1 [M+H] + .
[0280] Step 2: Compound S-53-a (220 mg, 522.59 μmol) was dissolved in DCM (20 mL), and then m-chloroperbenzoic acid (270.54 mg, 1.57 mmol) was added. The reaction was stirred at 20°C for 3 hours. After completion, the mixture was quenched with aqueous sodium bicarbonate solution, extracted with ethyl acetate, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain the crude product. Combiflash (12 g, 0-50% EA / PE) was used for separation and purification. Compound S-53-b (160 mg, 68%) was successfully obtained as a pale yellow solid. MS (ESI): 421.1 [M+H] + .
[0281] Step 3: Compound S-53-b (100 mg, 234.81 μmol) and intermediate 6 (186.87 mg, 662.28 μmol) were dissolved in water (0.5 mL) and 1,4-dioxane (4 mL). Sodium carbonate (116.99 mg, 1.10 mmol) and Pd(dppf)Cl2 (19.38 mg, 26.49 μmol) were then added. The reaction was stirred in a microwave oven at 120°C for 45 minutes. After the reaction was complete, the mixture was cooled to room temperature, diluted with dichloromethane, filtered, and the filtrate was concentrated under reduced pressure. The crude product was prepared by an alkaline method to afford compound S-53 (22.46 mg, 17.76%). 1H-NMR(400MHz,DMSO-d6)δ12.13(s,1H),7.29(s,1H),5.04(s,2H),4.53(s,2H),4.08(s,2H),3.62–3.50(m,1H),3.40(s,3H),3.09(s,2H),2 .56(s,3H),2.14(s,3H),1.23(t,J=7.5Hz,3H),1.08(s,1H),0.54(s,1H),0.37(d,J=6.3Hz,2H),0.22(d,J=5.7Hz,1H).MS(ESI):573.2[M+H] + .
[0282] The following example compounds were synthesized with reference to the preparation method of compound S-53.
[0283] Example 58 Preparation of Compound S-58
[0284] Step 1: Compound S-47-a (200 mg, 0.51 mmol) and 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (104 mg, 0.61 mmol) were dissolved in dioxane (10 mL) and water (1 mL). [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (42 mg, 0.05 mmol) and potassium carbonate (142 mg, 1.02 mmol) were then added. The reaction mixture was stirred at 90°C under nitrogen for 16 hours. The reaction mixture was cooled to room temperature and filtered. The filtrate was extracted three times with ethyl acetate and water. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography to obtain compound S-58-a (110 mg, colorless oil) in a yield of 54.1%. MS(ESI):397.0[M+H] + .
[0285] Step 2: Compound S-58-a (80 mg, 0.20 mmol) and N-methylmorpholine-N-oxide (24 mg, 0.20 mmol) were dissolved in tetrahydrofuran (8 mL) and water (8 mL), and potassium osmate (3 mg, 0.008 mmol) was added. The reaction solution was stirred at room temperature for 1 hour under nitrogen protection. The reaction solution was quenched with saturated sodium sulfite solution and extracted three times with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by preparative purification to obtain compound S-58 (6.48 mg, white solid) in a yield of 7.4%. MS (ESI): 431.1 [M+H] +. 1 H-NMR (400MHz, DMSO-d6) δ12.19(s,1H),7.79(s,1H),7.43(s,1H),4.74(s,2H),4.62(d,J=4.6Hz,1H),3.62(d,J=5.6Hz,3H) ,2.61(s,3H),2.16(s,3H),1.50(s,3H),1.31(d,J=6.8Hz,3H),1.16(s,1H),0.60(s,1H),0.43(d,J=6.0Hz,2H),0.26(s,1H).
[0286] Example 59 Preparation of Compound S-59
[0287] Step 1: Compound S-47-a (200 mg, 0.51 mmol) was dissolved in acetonitrile (10 mL), followed by the addition of trimethylsilyl chloride (56 mg, 0.51 mmol) and sodium iodide (231 mg, 1.53 mmol). The reaction mixture was stirred at 80°C under nitrogen for 2 hours. The reaction mixture was extracted twice with ethyl acetate and water. The organic phases were combined, backwashed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to afford compound S-59-a (100 mg, colorless oil) in a yield of 40.4%. MS (ESI): 483.0 [M+H] + .
[0288] Step 2: Compound S-59-a (250 mg, 0.51 mmol) and methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (3.0 g, 15.5 mmol) were dissolved in N,N-dimethylformamide (50 mL), followed by the addition of cuprous iodide (3.0 g, 15.5 mmol) and tris(dibenzylideneacetone)dipalladium (96 mg, 0.10 mmol). The reaction mixture was stirred at 80°C under nitrogen for 0.5 hours. The mixture was filtered, and the filtrate was extracted three times with ethyl acetate and water. The organic phases were combined, backwashed three times with water, then backwashed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by preparative purification to obtain compound S-59 (3.45 mg, white solid) in a yield of 1.5%. MS (ESI): 483.0 [M+H] + . 1H-NMR (400MHz, DMSO-d6) δ12.32(s,1H),8.16(s,1H),4.70(d,J=21.1Hz,2H),3.69–3.50(m,1H),2.66(d,J=8.4Hz,3H),2.18 (s,3H),1.29(d,J=6.8Hz,4H),1.18–1.08(m,1H),0.57(d,J=5.8Hz,1H),0.42(dd,J=12.9,6.2Hz,2H),0.26(d,J=5.4Hz,1H).
[0289] Example 60 Preparation of Compound S-60
[0290] Step 1: Intermediate 2 (500 mg, 1.38 mmol) and isopropenylboronic acid pinacol ester (243.97 mg, 1.45 mmol) were dissolved in dioxane (6 mL) and water (2 mL). 1,1'-Bis(diphenylphosphino)ferrocenepalladium(II) chloride (101.17 mg, 0.14 mmol) and sodium carbonate (293.11 mg, 2.77 mmol) were then added. The reaction was stirred at 120°C under microwave conditions for 45 minutes. The solvent was evaporated to dryness under reduced pressure, and the crude product was purified by Combiflash column separation (0-80% EA / PE) to afford compound S-60-a (365 mg, white solid) in a yield of 95.72%. MS (ESI): 276.1 [M+H]. + .
[0291] Step 2: Compound S-60-a (240 mg, 0.87 mmol) and 2-acetamido-4-methylthiazole (203.91 mg, 1.31 mmol) were dissolved in DMF (8 mL). Cesium carbonate (567.11 mg, 1.74 mmol), palladium acetate (58.62 mg, 0.26 mmol), and tri-tert-butylphosphine tetrafluoroborate (75.75 mg, 261.08 μmol) were then added. The reaction was stirred at 100°C under argon for 2 hours. The solvent was evaporated to dryness under reduced pressure, and the crude product was purified by Combiflash column separation (0-100% EA / PE) to afford compound S-60-b (20 mg, yellow solid) in a yield of 392.97%. MS (ESI): 396.0 [M+H]. + .
[0292] Step 3: Compound S-60-b (130 mg, 0.33 mmol) was dissolved in tetrahydrofuran (6 mL) and water (3 mL), followed by the addition of potassium osmate dihydrate (1.21 mg, 3.29 μmol) and N-methylmorpholine oxide (46.20 mg, 0.39 mmol). The reaction was stirred at 20°C for 20 hours. Saturated sodium sulfite solution was added to the reaction mixture, and the solvent was evaporated under reduced pressure. The crude product was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 0%-60% acetonitrile) to obtain the target product, compound S-60 (22.22 mg), in a yield of 15.70%. MS (ESI): 430.2 [M+H] + . 1 H-NMR (400MHz, DMSO-d6) δ12.16(s,1H), 7.59(s,1H), 7.47(s,1H), 7.32(s,1H), 4.76-4.66(m,3H), 3.64-3.59(m,3H), 2.40(s, 3H), 2.16(s,3H), 1.50(s,3H), 1.32-1.29(m,3H), 1.16-1.12(m,1H), 0.60-0.58(m,1H), 0.45-0.40(m,2H), 0.27-0.24(m,1H).
[0293] Example 61 Preparation of Compound S-61
[0294] Step 1: Dissolve Intermediate 5 (5 g, 18.44 mmol), Intermediate 6 (9.366 g, 33.19 mmol), and anhydrous sodium carbonate (3.9 g, 36.88 mmol) in 1,4-dioxane (50 mL) and replace the atmosphere with argon. Add Pd(dppf)Cl2 (675 mg, 0.922 mmol), replace the atmosphere with argon, and stir at 100°C for 2 hours. A large amount of yellow solid precipitates. LCMS confirms the reaction is complete. The reaction mixture is cooled to room temperature. Filter the reaction mixture, drain the filter cake, and rinse with a small amount of dichloromethane (15 mL). Dry the filter cake to obtain S-47-a (4.1 g, light yellow solid) in a yield of 56.88%. MS (ESI): 391.1 [M+H]. + .
[0295] Step 2: Dissolve S-47-a (2.2 g, 5.63 mmol) in N,N-dimethylformamide (20 mL). Add triethylamine (1.5 g, 14.2 mmol), bis(triphenylphosphine)palladium dichloride (360 mg, 0.5 mmol), and tributyl(1-ethoxyethylene)tin (2.4 g, 6.8 mmol). Strictly replace the argon atmosphere with the reaction mixture and stir at 100°C for 16 hours. LCMS monitoring indicates product formation. Cool the reaction mixture to room temperature, dilute with ethyl acetate (30 mL), and wash with water (20 mL x 3) and saturated brine (20 mL x 2). Separate the mixture, dry the organic phase over anhydrous sodium sulfate, filter, and concentrate under reduced pressure. The crude product was dissolved in an appropriate amount of dichloromethane (approximately three times the volume of the crude product). Petroleum ether (approximately five times the volume of dichloromethane) was slowly added with stirring until a large amount of light yellow solid precipitated. Stirring was continued for 30 minutes, and the mixture was filtered. The filter cake was rinsed with a mixed solvent of DCM:PE = 1:6 (10 ml x 3) and dried to obtain compound S-47-b (2 g, light yellow solid powder). MS (ESI): 427.2 [M+H] + . 1 H-NMR (400MHz, DMSO-d6) δ12.20(s,1H),7.85(s,1H),4.60(s,2H),4.52(d,J=3.4Hz,2H),3.93(dd,J=13.6,6.7Hz,2H),3.65–3. 49(m,1H),2.61(s,3H),2.16(s,3H),1.29–1.26(m,3H),1.12(s,1H),0.56(s,1H),0.39(d,J=6.6Hz,2H),0.24(d,J=5.8Hz,1H).
[0296] Step 3: Dissolve compound S-47-b (2 g, 4.7 mmol) in acetone (50 ml), place in an ice-water bath, add hydrochloric acid (8 ml, 2 mol / L), protect with argon, and stir at 0°C for 1 hour. LCMS monitoring indicates product formation. Pour the reaction solution into saturated sodium bicarbonate aqueous solution (100 mL) containing ice, extract with dichloromethane (100 mL x 3), separate the layers, dry the organic phase over anhydrous sodium sulfate, filter, and concentrate under reduced pressure to obtain compound S-47-c (1.5 g, yellow solid, purity: 94.9%). MS (ESI): 399.1 [M+H] + .
[0297] Step 4: Dissolve compound S-47-c (300 mg, 0.753 mmol) and 2-methylpropane-2-sulfonamide (547 mg, 4.52 mmol) in tetrahydrofuran (20 mL). Add tetraethyl titanate (515 mg, 2.26 mmol), replace the mixture with argon, and stir at 70°C for 16 hours. LCMS analysis indicates the reaction is complete. After cooling, add water (100 mL) and dichloromethane (200 mL), stir for 5 minutes, filter, and wash the residue with dichloromethane (100 mL x 3). The collected filtrate is separated using a separatory funnel, and the organic phase is washed with 100 mL of saturated sodium chloride solution and dried over anhydrous sodium sulfate. Purify the mixture by spin drying on a normal phase column to obtain compound S-61-a (300 mg, purity: 93.32%). MS (ESI): 502.2 [M+H] + .
[0298] Step 5: Dissolve compound S-61-a (300 mg, 0.598 mmol) in dichloromethane (20 ml), replace with argon, and protect with argon. Cool the reaction system to -48 ° C, slowly add methylmagnesium bromide (1M, 2 mL), return to room temperature after addition, and stir to react for 4 hours. LCMS detection shows that the reaction is successful. Pour the reaction solution into ice water (50 mL), extract with dichloromethane (100 mL × 3), and wash the collected organic phase with saturated sodium chloride aqueous solution (50 mL) and dry over anhydrous sodium sulfate. Spin dry and purify on a normal phase column to obtain compound S-61-b (212 mg). 1 H-NMR (400MHz, DMSO-d6) δ12.29(s,1H),9.00(s,2H),7.96(s,1H),4.80(s,2H),3.64(dd,J=9.0,6.9Hz,1H),2.63(s,3H),2.18(s,3H ),1.77(d,J=1.6Hz,6H),1.32(d,J=6.8Hz,3H),1.17(dd,J=4.2,2.6Hz,1H),0.65–0.58(m,1H),0.46–0.39(m,2H),0.30–0.24(m,1H).
[0299] Step 6: Dissolve compound S-61-b (212 mg, 0.409 mmol) in 1,4-dioxane (15 mL) under argon. Add 1,4-dioxane hydrochloride (1 mL) and stir for 10 minutes. The reaction is complete. Pour the reaction solution into 20 mL of water and extract with a dichloromethane / methanol mixture (10:1 by volume) (30 mL x 8). Dry the organic phase over anhydrous sodium sulfate. Concentrate under reduced pressure and purify with a preparative column to obtain compound S-61 (11.65 mg, light yellow solid). Yield: 6.88%.1 H-NMR (400MHz, DMSO-d6) δ8.36(s,1H),7.82(s,1H),4.70(s,2H),3.66–3.62(m,1H),2.62(s,3H),2.16(s,3H),1.59(d,J=1.2H z,6H),1.30(d,J=6.8Hz,3H),1.15(dt,J=12.3,5.9Hz,1H),0.63–0.56(m,1H),0.46–0.38(m,2H),0.27(dd,J=9.5,4.4Hz,1H).
[0300] Example 62 Preparation of Compound S-62
[0301] Step 1: Dissolve compound S-19-b (800 mg, 2.88 mmolq) and 2-methylpropane-2-sulfonamide (2.094 g, 17.28 mmol) in tetrahydrofuran (30 mL). Add tetraethyl titanate (1.970 g, 8.64 mmol). Replace the mixture with argon. Stir the mixture at 70°C under argon protection for 16 hours. LCMS analysis indicates the reaction is complete. After cooling, add water (100 mL) and dichloromethane (200 mL). Stir for 5 minutes, filter, and wash the residue with dichloromethane (100 mL x 3). Combine the filtrates, separate them using a separatory funnel, and wash the organic phase with saturated sodium chloride solution and dry over anhydrous sodium sulfate. Spin dry and purify the mixture via column chromatography to obtain compound S-62-a (800 mg, purity: 83.43%) in a yield of 60.83%. 1 H-NMR (400MHz, DMSO-d6) δ7.81(s,1H),7.37(s,1H),4.58(d,J=10.3Hz,2H),4.09(q,J=5.3Hz,1H),2.6 9(s,2H),2.47(s,1H),1.31–1.09(m,13H),0.61–0.53(m,1H),0.44–0.34(m,2H),0.23(d,J=5.3Hz,1H).
[0302] Step 2: Dissolve compound S-62-a (600 mg, 1.31 mmol, purity: 83.43%), 4-methylthiazol-2-ylacetamide (307 mg, 1.97 mmol), cesium carbonate (854 mg, 2.62 mmol), and (t-Bu)3PHBF4 (152 mg, 0.524 mmol) in DMF (10 ml). Displace the argon atmosphere with the addition of palladium(II) acetate (117 mg, 0.524 mmol). Displace the argon atmosphere with the addition of palladium(II) acetate (117 mg, 0.524 mmol). Stir the mixture at 100°C under argon protection for 10 hours. LCMS analysis indicated the reaction was complete. After cooling, the reaction mixture was added with water (100 mL) and dichloromethane (100 mL). Stir and separate using a separatory funnel. The aqueous phase was re-extracted with dichloromethane (100 mL x 2). The organic phases collected from the three fractions were washed with saturated sodium chloride aqueous solution and dried over anhydrous sodium sulfate. The residue was dried and purified by column chromatography to obtain compound S-62-b (550 mg, purity: 65.90%), with a yield of 22.59%.
[0303] Step 3: Dissolve compound S-62-b (550 mg, 0.724 mmol, purity: 65.90%) in dichloromethane (200 mL), replace the atmosphere with argon, and protect with argon. Cool the reaction system to -48°C and slowly add methylmagnesium bromide (1 M, 2 mL) dropwise. After complete addition, return to room temperature and stir for 4 hours. LCMS analysis confirmed successful reaction. Pour the reaction solution into ice water (50 mL) and extract with dichloromethane (100 mL x 3). The collected organic phase was washed with saturated sodium chloride solution and dried over anhydrous sodium sulfate. The mixture was spin-dried and purified by column chromatography to obtain compound S-62-c (180 mg, purity: 85.29%) in a yield of 41.04%.
[0304] Step 4: Dissolve compound S-62-c (180 mg, 0.297 mmol, purity: 85.29%) in 1,4-dioxane (15 mL) under argon. Add 1,4-dioxane hydrochloride (1 mL) and stir for 10 minutes. The reaction is complete. Pour the reaction solution into water (20 mL) and extract with a dichloromethane / methanol mixture (10:1 by volume) (30 mL x 8). Dry the organic phase over anhydrous sodium sulfate. Spin dry and send for preparative purification to obtain compound S-62 (15.60 mg, white solid) in a yield of 12.73%. 1H-NMR (400MHz, DMSO-d6) δ8.37(s,1H),7.67(s,1H),7.49(s,1H),4.68(s,2H),3.66(d,J=9.2Hz,1H),2.42(s,3H),2.16(s,3H),1. 64(s,6H),1.32(d,J=6.8Hz,3H),1.18–1.13(m,1H),0.63–0.58(m,1H),0.41(dd,J=8.7,5.3Hz,2H),0.26(dd,J=10.5,5.1Hz,1H).
[0305] Example 63 Preparation of Compound S-63
[0306] Compound S-47-a (578 mg, 1.48 mmol) and intermediate 15 (15, 200 mg, 1.48 mmol) were dissolved in toluene (20 ml), followed by the addition of tris(dibenzylideneacetone)dipalladium (136 mg, 0.014 mmol), 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl (139 mg, 0.29 mmol), and cesium carbonate (966 mg, 2.96 mmol). The reaction mixture was incubated at 110°C under a nitrogen atmosphere for 16 hours. The reaction mixture was cooled to room temperature and extracted three times with ethyl acetate and water. The organic phases were combined and backwashed once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was purified by preparative purification to afford compound S-63 (6.61 mg, white solid) in a yield of 1%. MS (ESI): 490.2 [M+H] + ; 1 H-NMR(400MHz,DMSO-d6)δ12.25(s,1H),8.44(d,J=6.0Hz,1H),7.80(s,1H),6 .69(d,J=6.1Hz,1H),4.65(s,2H),3.91–3.85(m,2H),3.50(d,J=6.8Hz,3H),3 .12(t,J=6.4Hz,2H),2.58(s,3H),2.15(s,3H),1.26(d,J=6.8Hz,3H),1.14–1 .07(m,1H),0.59–0.53(m,1H),0.43–0.32(m,2H),0.21(td,J=9.0,4.7Hz,1H).
[0307] Example 64 Preparation of Compound S-64
[0308] Compound S-47-c (50 mg, 0.125 mmol, 1 eq) was placed in a clean 25 mL three-necked flask. 2 mL of tetrahydrofuran was added and the temperature was cooled to 0°C. Sodium borohydride (14 mg, 0.376 mmol, 3 eq) was slowly added and stirred at 0°C for 1 hour. LCMS confirmed the complete reaction. The reaction mixture was poured into ice water and extracted with dichloromethane (10 mL x 3). The organic phases were combined, washed with saturated brine, and the layers separated. The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound S-64 (20 mg, white solid) was purified by silica gel column chromatography using petroleum ether / ethyl acetate = 7:1 as eluent to afford compound S-64 (40% yield). 1 H NMR (400MHz, DMSO-d6) δ12.02(s,1H),7.79(s,1H),6.01(t,J=7.5Hz,1H),5.22(m,1H),4.70(s,2H),3.60(dq,J=13.7,6.8Hz,1H),2.61 (s,3H),2.16(s,3H),1.46(d,J=6.6Hz,3H),1.30(d,J=6.8Hz,3H),1.14(dt,J=12.6,6.4Hz,1H),0.59(m,1H),0.41(m,2H),0.26(m,1H).
[0309] Test Example 1: Inhibition of Akt S473 phosphorylation level in Raw264.7 cells
[0310] This experiment used ELISA method for detection.
[0311] 1. Raw264.7 Cell Processing
[0312] Raw264.7 cells (PI3Kγ) in the logarithmic growth phase were plated at appropriate concentrations in 96-well plates (Falcon 353072) and cultured overnight at 37°C, 5% CO2. After cells adhered, 10 μL of a DMSO solution of the test compound at various concentrations was added (control wells received only DMSO) and incubated at 37°C, 5% CO2. After 2 hours, 5 μL of mC5a in serum-free DMEM (R&D 2150-C5) was added (blank wells received only medium). After incubation at room temperature for 5 minutes, the medium was removed and 100 μL of 1X cell lysis buffer (CST 9806S) (CST 5872S) was added. The cells were shaken at 800 rpm for 1 minute and stored at -80°C until use.
[0313] 2. Detection steps
[0314] Capture solution was prepared according to the ELISA detection kit for phosphorylated Akt S473 (R&D DYC887BE), 100 μL per well was added to a high binding 96-well plate (Costar 42592), and incubated at room temperature overnight. The cells were washed three times with 300 μL PBST, and blocking solution (1% (w / v) BSA in PBS) (Genview FA016-100G) was added, incubated at room temperature for 2 hours, and washed three times with 300 μL PBST; 90 μL of cell sample was added, incubated at room temperature for 2 hours, and washed three times with 300 μL PBST; 100 μL of anti-pAkt S473 diluted solution was added, incubated at room temperature for 2 hours, and washed three times with 300 μL PBST; 100 μL of Streptavidin-HRP (horseradish peroxidase-labeled streptavidin) diluted solution was added, incubated at room temperature for 40 minutes, and washed three times with 300 μL PBST; 100 μL of ELISA reaction substrate TMB (tetramethylbenzidine) was added, incubated at room temperature for 20 minutes, and the reaction was terminated by adding 50 μL of 2N H2SO4 solution. The OD values were read on an Infinite M1000 fluorescence microplate reader (Tecan) at absorbance wavelengths of 450 nm and 570 nm.
[0315] 3. Data Analysis
[0316] The cells with DMSO but no mC5a were used as background, and the cells with DMSO and mC5a were used as blank controls.
[0317] Inhibition%=[1-(Total mean (Inhibitor)-total mean (background)) / (Total mean (blank)-total mean (background))]×100%
[0318] 2.4 The calculated inhibition rate was calculated using XLFIT 5.0 software to calculate IC 50 The test results are shown in Table 1.
[0319] Table 1: IC values of compounds for inhibition of RAW264.7 cell activity 50 value
[0320] Test Example 2: Inhibition of Akt S473 phosphorylation levels in T47D and PC3 cells
[0321] This experiment used the Incell ELISA method for detection.
[0322] 1. Treatment of T47D and PC3 cells
[0323] Logarithmically growing T47D (PI3Kα) and PC3 (PI3Kβ) cells were plated in 96-well plates (Falcon 353072) at appropriate concentrations in 90 μL format and cultured at 37°C, 5% CO2. After the cells adhered overnight, 10 μL of a DMSO solution of the test compound at different concentrations was added (DMSO alone for the blank and 10 μM YZJ-0673 for the background), and the cells were cultured at 37°C, 5% CO2. After 2 hours, 100 μL of 4% paraformaldehyde (Biosharp BL539A) was added. The cells were incubated at room temperature for 45 minutes, removed, and 100 μL of a 0.1% Triton X-100 solution was added, and the cells were incubated for another 30 minutes.
[0324] 2. Detection steps
[0325] Remove the Triton X-100 solution, wash twice with 200 μL of PBS (300 rpm, 1 minute), add blocking solution (1% BSA in PBS) (Genview FA016-100G), incubate at room temperature for 2 hours, remove, wash once with PBS (300 rpm, 1 minute), add 30 μL of Ser473-p-Akt antibody diluted in 0.1% BSA (Cell Signaling 4060L), and incubate overnight at 4°C. Remove the Ser473-p-Akt antibody, wash twice with PBS (300 rpm, 1 minute), add 100 μL of HRP anti-rabbit IgG diluted in 0.1% BSA (CST 7074S), and incubate at room temperature for 1.5 hours. The cells were washed twice with PBS (300 rpm, 1 min), and 100 μL of ELISA substrate TMB was added. After incubation at room temperature for 0.5 h, 50 μL of 2N sulfuric acid was added to terminate the reaction. After incubation at room temperature for 20 min, the OD value was read on an Infinite M1000 fluorescence microplate reader (Tecan) at an absorption wavelength of 450 nm.
[0326] The TMB solution was removed, and the cells were washed three times with PBS (300 rpm, 1 min). 100 μL of 0.1% Janus aqueous solution (Abcam ab111622) was added and incubated at room temperature for 10 min. The Janus solution was removed, and the cells were washed twice with water five times (300 rpm, 1 min). 100 μL of 1.5 M hydrochloric acid was added and incubated at room temperature for 10 min. The OD value was read on an Infinite M1000 fluorescence microplate reader (Tecan) at an absorption wavelength of 595 nm.
[0327] 3. Data Analysis
[0328] 10 μM YZJ-0673 was added as background, and DMSO was added as blank control. Ratio = OD450 / OD595.
[0329] Inhibition% = [1-(Ratio(Inhibitor)-Ratio(Background)) / (Ratio(Blank)-Ratio(Background))] × 100%. The calculated inhibition rate was calculated using XLFIT 5.0 software to calculate the IC 50 The test results are shown in Table 2.
[0330] Test Example 3: Inhibition of Akt S473 phosphorylation level in Raji cells
[0331] This experiment used ELISA method for detection.
[0332] 1. Raji cell treatment
[0333] Raji cells (PI3Kδ) in logarithmic growth phase were plated at 45 μL of the appropriate concentration in a 96-well V-shaped plate (Costar 3894). 5 μL of a DMSO solution of the test compound at various concentrations was added (control wells received only DMSO) and incubated at 37°C, 5% CO2. After 2 hours, 10 μL of anti-Human IgM in 1640 serum-free medium (Sigma I0759-5X1MG) was added (blank wells received only medium). After incubation at room temperature for 10 minutes, the medium was removed, and 60 μL of 2X cell lysis buffer (CST 9806S) (CST 5872S) was added. The plates were shaken at 800 rpm for 1 minute and stored at -80°C until use.
[0334] 2. Detection steps
[0335] Capture solution was prepared according to the ELISA detection kit for phosphorylated Akt S473 (R&D DYC887BE), 100 μL per well was added to a high binding 96-well plate (Costar 42592), and incubated at room temperature overnight. The cells were washed three times with 300 μL of PBST, and blocking buffer (1% BSA in PBS) (Genview FA016-100G) was added, incubated at room temperature for 2 hours, and washed three times with 300 μL of PBST. 90 μL of cell sample was added, incubated at room temperature for 2 hours, and washed three times with 300 μL of PBST. 100 μL of anti-pAkt S473 diluted solution was added, incubated at room temperature for 2 hours, and washed three times with 300 μL of PBST. 100 μL of Streptavidin-HRP diluted solution was added, incubated at room temperature for 40 minutes, and washed three times with 300 μL of PBST. 100 μL of ELISA substrate TMB was added, incubated at room temperature for 20 minutes, and the reaction was terminated by adding 50 μL of 2N H2SO4 solution. OD values were read on an Infinite M1000 fluorescence microplate reader (Tecan) at absorbance wavelengths of 450 nm and 570 nm.
[0336] 3. Data Analysis
[0337] OD = OD450 - OD570. DMSO without anti-human IgM served as the background control, while DMSO and anti-human IgM served as the blank control. Inhibition % = [1 - (OD(Inhibitor) - OD(Background)) / (OD(Blank) - OD(Background))] × 100%. The calculated inhibition rate was used to calculate the IC using XLFIT 5.0 software. 50 The test results are shown in Table 2.
[0338] Table 2 IC inhibition of compounds on T47D, PC3 and Raji cell activity 50 value
[0339] Test Example 4: In vivo pharmacokinetic study in mice
[0340] The LC / MS / MS method was used to determine the drug concentrations in the plasma of mice at different times after intravenous injection and oral gavage of the compounds of the present application. Taking the existing compound D1 and the compounds S-19, S-47, and S-64 of the present application as examples, the pharmacokinetic behavior of the compounds of the present application in mice was studied and their pharmacokinetic characteristics were evaluated.
[0341] The structure of compound D1 (CAS No. 2504036-13-7) is shown below, and it can be prepared by referring to existing literature or purchased commercially.
[0342] Experimental plan:
[0343] Experimental animals: Healthy adult male ICR mice (25-40 g, 12 mice; mice in the intravenous injection group had free access to water and food; mice in the oral administration group were fasted overnight and had free access to water and food 4 h after administration) were provided by Beijing Vital River Laboratory Animal Co.LTD.
[0344] Administration and Dosage: Animals meeting experimental requirements were selected, weighed, and labeled prior to administration. ICR mice were administered via tail vein administration (2 mg / kg, 5% DMSO + 30% (10% Solutol HS15) + 65% (20% Captisol, pH 7.4)) and oral gavage (10 mg / kg, 5% DMSO + 30% (10% Solutol HS15) + 65% (20% Captisol, pH 7.4)).
[0345] Blood Sampling: Prior to blood collection, mice were restrained and approximately 100 μL of blood was collected from the canthal vein at the designated time points (intravenous administration: 0.083, 0.25, 0.5, 1, 2, 4, 7, and 24 hours after dosing, for a total of eight time points; oral administration: 0.083, 0.25, 0.5, 1, 2, 4, 7, and 24 hours after dosing, for a total of eight time points). Whole blood was transferred to a 1.5 mL tube pre-spiked with K2EDTA (Sigma-ACDRICH, WXBB0768) and centrifuged for 6 minutes (8000 rpm, 4°C) to separate plasma. This process was completed within 15 minutes of blood collection. All samples were stored at -20°C until analysis.
[0346] Analytical method: Plasma samples were analyzed by liquid chromatography-tandem mass spectrometry (model: Triple QuadTM 4000) using a Waters XBridge-C18 column (2.1×50 mm, 3.5 μm).
[0347] Preparation of standard curve samples: Prepare standard curve samples with a linear range of 1.00-3000 ng / mL for the test compound in blank ICR mouse plasma matrix, and prepare low, medium and high concentration quality control samples with concentrations of 3,500, and 2400 ng / mL.
[0348] Processing of biological samples: Frozen plasma samples were thawed on wet ice. Once thawed, they were vortexed for 5 minutes. 20 μL of plasma sample, standard curve sample, and quality control sample were added to a 96-well plate. Protein was precipitated by adding 200 μL of acetonitrile containing the internal standard dexamethasone (brand: NIFDC, lot number: 6TUC-T4C2, prepared at a concentration of 2000 ng / mL). The plates were vortexed for 5 minutes and then centrifuged at 3700 rpm and 4°C for 15 minutes. The supernatant was extracted and centrifuged again under the same conditions. Finally, 2 μL of the supernatant was transferred for LC-MS / MS analysis. The test results are shown in Table 3.
[0349] Table 3 Pharmacokinetic data of compounds in mice
[0350] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of this application, those skilled in the art may make various changes or modifications to this application, and that such equivalents also fall within the scope of the claims appended hereto.
[0351] The technical features of the above-mentioned embodiments can be combined arbitrarily. In order to make the description concise, not all possible combinations of the technical features in the above-mentioned embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0352] The above-described embodiments merely represent several implementation methods of the present application. While the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the patent application. It should be noted that a person of ordinary skill in the art may make various modifications and improvements without departing from the spirit of the present application, and these modifications and improvements fall within the scope of protection of the present application. Therefore, the scope of protection of the present patent application shall be determined by the appended claims.
Claims
1. A compound having a structure represented by formula (I), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof: in, Ring A is a 5- or 6-membered heteroaryl ring; (R0) n Indicates that the hydrogen on ring A is replaced by n R0, n is 0, 1, 2, 3 or 4; each R0 is the same or different and independently represents deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, NR a1 R b1 、-N(R a3 )-C(O)C 1-3 Alkyl, -N(R a3 )-C(O)-deuterated C 1-3 Alkyl, -N(R a3 )-C(O)OC 1-3 Alkyl, -SO2C 1-3 Alkyl, -SO2C 3-6 Cycloalkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl; wherein the 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl are each independently unsubstituted or substituted by 1, 2, or 3 substituents each independently selected from Substituent Group Q; Z is N or CR z ; R z is hydrogen, halogen or C 1-8 alkyl; U is N or CH; W is cyano, ethynyl, -NHSO2N(CH3)2, 5- or 6-membered heteroaryl, or a structure represented by formula (Ia), (Ib), (Ic) or (Id): R a 、R b are each independently halogen, C 1-8 Alkyl, hydroxy substituted C 1-8 Alkyl or C 3-6 Cycloalkyl; R c For hydroxyl, halogen, C 1-3 Alkyl, deuterated C 1-3 Alkyl, C 3-6 Cycloalkyl, halogenated C 1-3 Alkyl or NR a1 R b1 ; Y is C or N; is a 5- or 6-membered heteroaryl ring, or a benzene ring; p and q are each independently 0, 1, 2 or 3; R w1 、R w2 、R w3 、R w4 are independently hydrogen, cyano, halogen, C 1-3 Alkyl, halogenated C 1-3 Alkyl, -N(R a3 )-C(O)C 1-3 Alkyl, -SO2C 1-3 Alkyl, -C(O)NR a1 R b1 or NR a1 R b1 ; p1, p2, q1, q2 are each independently 1, 2 or 3; R d is a halogen; L 21 、L 22 Each independently is -(CR e2 R f2 ) m2 -; m2 is 1, 2 or 3; Y2 is NR g2 or O; R e2 、R f2 are independently hydrogen, hydroxy, oxo, C 1-3 Alkyl or -C(O)C 1-3 alkyl; R g2 For hydrogen, C 1-3 Alkyl or -C(O)C 1-3 alkyl; R1 and R2 are each independently C 1-8 Alkyl, halogenated C 1-8 Alkyl or C 3-6 Cycloalkyl; the C 3-6 Cycloalkyl is unsubstituted or substituted by 1 or 2 groups independently selected from halogen and C 1-3 Substitution of alkyl groups; The substituent group Q is selected from halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkyne C 1-3 Alkyl, halogenated C 1-3 Alkoxy, NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl; R a1 、R b1 are independently hydrogen, C 1-3 Alkyl or acetyl, or R a1 、R b1 Together with the nitrogen atom to which it is connected, it forms a 4- to 6-membered saturated monocyclic heterocycle; the 4- to 6-membered saturated monocyclic heterocycle is unsubstituted or substituted by 1, 2 or 3 substituents independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NH2, -C(O)NH(C 1-3 alkyl), -C(O)N(C 1-3 Alkyl)2, -C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 cycloalkyloxy and 3- to 6-membered heterocycloalkyl; R a3 is hydrogen or C 1-8 alkyl.
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: W is cyano, ethynyl, -NHSO2N(CH3)2 or a 5- or 6-membered heteroaryl selected from the group consisting of thienyl, furyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, pyrrolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, tetrazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and tetrazinyl.
3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: The 5- or 6-membered heteroaryl group in W is selected from one of the following structures:
4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: Formula (Ia) is selected from one of the following structures:
5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: is a benzene ring or a 5- or 6-membered heteroaryl ring selected from the group consisting of a thiophene ring, a furan ring, a thiazole ring, an isothiazole ring, an imidazole ring, an oxazole ring, a pyrrole ring, a pyrazole ring, a 1,2,3-triazole ring, a 1,2,4-triazole ring, a 1,2,5-triazole ring, a 1,3,4-triazole ring, a tetrazole ring, an isoxazole ring, a 1,2,3-oxadiazole ring, a 1,2,4-oxadiazole ring, a 1,2,5-oxadiazole ring, a 1,3,4-oxadiazole ring, a thiadiazole ring, a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a triazine ring and a tetrazine ring.
6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: Formula (Ib) is selected from one of the following structures:
7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: The structure represented by formula (Ic) is selected from the following structures:
8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: The structure represented by formula (Id) is selected from the following structures:
9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: Ring A is a 5- or 6-membered heteroaryl ring selected from the group consisting of a thiophene ring, a furan ring, a thiazole ring, an isothiazole ring, an imidazole ring, an oxazole ring, a pyrrole ring, a pyrazole ring, a 1,2,3-triazole ring, a 1,2,4-triazole ring, a 1,2,5-triazole ring, a 1,3,4-triazole ring, a tetrazole ring, an isoxazole ring, a 1,2,3-oxadiazole ring, a 1,2,4-oxadiazole ring, a 1,2,5-oxadiazole ring, a 1,3,4-oxadiazole ring, a thiadiazole ring, a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a triazine ring, and a tetrazine ring.
10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: In formula (I), It is the structure shown in formula (a): R 01 、R 02 are independently deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 ene Base, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, NR a1 R b1 、-N(R a3 )-C(O)C 1-3 Alkyl, -N(R a3 )-C(O)-deuterated C 1-3 Alkyl, -N(R a3 )-C(O)OC 1-3 Alkyl, -SO2C 1-3 Alkyl, -SO2C 3-6 Cycloalkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl or 5- to 6-membered heteroaryl; wherein the 3- to 6-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaryl are each independently unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from Substituent Group Q.
11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: R 01 Halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkyl or halogenated C 1-3 Alkoxy; R 02 -NH-C(O)C 1-3 Alkyl, -NH-C(O)-deuterated C 1-3 Alkyl or -NH-C(O)OC 1-3 alkyl.
12. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: R1 is monochloromethyl, dichloromethyl, trichloromethyl, monochloroethyl, 1,2-dichloroethyl, trichloroethyl, monobromoethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, monofluoro-substituted cyclopropyl or monofluoro-substituted cyclobutyl; R2 is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, monofluoro-substituted cyclopropyl or monofluoro-substituted cyclobutyl.
13. The compound according to claim 12, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: In formula (I), Select one of the following structures:
14. The compound according to claim 13, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: In formula (I), Select one of the following structures:
15. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: Z is N or CH.
16. The compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: The compound of formula (I) is selected from one of the following structures:
17. A pharmaceutical composition, wherein The invention comprises the compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof; and a pharmaceutically acceptable carrier.
18. Use of the compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or the pharmaceutical composition according to claim 17 in the preparation of a medicament for treating or preventing a disease associated with or mediated by PI3Kγ activity.
19. The use according to claim 18, wherein: The disease associated with PI3Kγ activity or mediated by PI3Kγ activity is inflammation, metabolic disease or cancer.
20. The compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or the pharmaceutical composition according to claim 17 for use in treating or preventing a disease associated with or mediated by PI3Kγ activity.
21. A method for treating or preventing a disease associated with or mediated by PI3Kγ activity, comprising administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a therapeutically effective amount of a pharmaceutical composition according to claim 17.
Citation Information
Cited By
Synthesis method of 2-bromo-4-(piperidinyl methyl) pyridine
CN119912427A
